Uncover valuable tips for nerve block management to help manage your headaches in the hemicrania continua effectively.

Abstract

Headache disorders represent one of the most prevalent and debilitating neurological conditions affecting patients worldwide, with certain subtypes — including hemicrania continua — presenting particular diagnostic and therapeutic challenges for clinicians. This educational post, authored by Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, draws from a live clinical demonstration and integrates the most current, evidence-based research to provide a thorough, accessible exploration of peripheral nerve block therapy for the management of refractory headache conditions in real-world clinical settings.

In this post, we examine the neuroanatomy of the four primary sensory nerves targeted during peripheral nerve blockade of the head — the supratrochlear nerve, the supraorbital nerve, the zygomaticotemporal nerve, and the auriculotemporal nerve — and explain the critical role each plays in the transmission of cranial pain signals. We explore the pharmacological rationale for combining lidocaine with epinephrine and bupivacaine for local anesthetic blocks, the procedural technique required for safe and effective administration, and the immediate clinical outcomes observed after nerve blockade.

Beyond the injection procedure itself, this post situates peripheral nerve block therapy within the broader context of integrative, multidisciplinary care — the model practiced at Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas. Here, Dr. Jimenez collaborates daily with Dr. Maria Guadalupe Cardenas, MD, a board-certified internist who serves as Medical Director and Collaborative Physician and brings more than 40 years of experience to the team. Together, their practice integrates chiropractic care, functional medicine, internal medicine oversight, personal injury care, and rehabilitative services into a cohesive, patient-centered framework.

We discuss how chiropractic manipulation, soft tissue therapy, functional nutritional strategies, and neuromodulatory interventions complement peripheral nerve block therapy to achieve durable outcomes for patients suffering from chronic headache, hemicrania continua, cervicogenic headache, and related pain syndromes. The physiological underpinnings of each approach are explored in depth, supported by current peer-reviewed literature and grounded in the clinical observations and professional practice of Dr. Jimenez. By the end of this post, readers will have a comprehensive, clinically meaningful understanding of why peripheral nerve blocks work, how they are performed, who benefits most, and how they fit into an integrated, whole-patient approach to headache management.

Understanding Hemicrania Continua: The Diagnosis Behind the Procedure

What Is Hemicrania Continua and Why Does It Matter?

Before we can fully appreciate the significance of the peripheral nerve block procedure described in this clinical demonstration, we must develop a thorough understanding of hemicrania continua (HC)—the specific headache disorder affecting the patient in this case. HC is not simply a severe or persistent headache. It is a classified primary headache disorder with distinct diagnostic criteria, a unique pathophysiological profile, and a set of clinical features that clearly differentiate it from more common headache types such as migraine or tension-type headache.

According to the International Classification of Headache Disorders, Third Edition (ICHD-3), hemicrania continua is defined as a persistent, strictly unilateral headache present continuously—meaning without pain-free remission periods—for at least three months (Headache Classification Committee of the International Headache Society, 2018). The pain is typically moderate in baseline intensity but is punctuated by exacerbations of severe pain that can last from minutes to days. These exacerbations are commonly accompanied by ipsilateral autonomic features, which may include conjunctival injection (redness of the eye on the affected side), lacrimation (tearing), nasal congestion or rhinorrhea, ptosis (drooping eyelid), miosis (constricted pupil), eyelid edema, and a sensation of facial flushing or sweating.

One of the most clinically important and defining characteristics of HC is its absolute responsiveness to indomethacin, a nonsteroidal anti-inflammatory drug (NSAID). In fact, the ICHD-3 criteria require that the headache completely resolves with therapeutic doses of indomethacin (typically 150 mg per day or less) as a diagnostic criterion. This indomethacin-responsiveness is so specific to HC — and to the related condition, paroxysmal hemicrania — that a positive therapeutic response is considered virtually pathognomonic. However, indomethacin carries significant gastrointestinal, renal, and cardiovascular risks, particularly in older patients and those with comorbidities, making long-term use problematic (Prakash & Shah, 2010).

The 71-year-old female patient presented in this clinical demonstration exemplifies the typical clinical picture of HC. She reports a right-sided headache, consistent with the strictly unilateral nature of the condition. Her pain, rated at a seven out of ten before the procedure, reflects the moderate-to-severe baseline pain intensity that characterizes this disorder. Her presentation prompted Dr. Jimenez to perform a systematic physical examination of the peripheral sensory nerve distribution across the right side of her face and scalp, identifying four discrete points of tenderness corresponding to the targeted sensory nerves. This diagnostic precision is essential — not every patient with a unilateral headache has HC, and accurate identification of the underlying headache type determines whether peripheral nerve blockade is an appropriate therapeutic intervention.

The Epidemiology and Clinical Significance of Hemicrania Continua

HC is widely underdiagnosed in clinical practice, largely because many clinicians remain unfamiliar with its specific diagnostic criteria and because its symptoms can superficially resemble those of chronic migraine, cluster headache, or trigeminal autonomic cephalalgias (TACs). Population-based prevalence data are limited, but clinical studies suggest that HC may account for a meaningful proportion of patients presenting to specialized headache clinics with refractory unilateral pain (Cittadini & Goadsby, 2010).

The condition affects women more frequently than men, with a female-to-male ratio of approximately 2:1 in most reported series. Age of onset is variable but most commonly occurs in the third to fifth decades of life, though cases in elderly patients — as seen in the current case — are well documented (Marmura, Silberstein, & Schwedt, 2015). The continuous, unrelenting nature of HC carries a significant burden of disability, affecting occupational function, social participation, sleep quality, and psychological well-being. Patients with HC often report years of misdiagnosis and inadequate treatment before receiving appropriate care.

The pathophysiology of HC remains incompletely understood, but current evidence strongly implicates hypothalamic dysfunction — specifically, posterior hypothalamic activation — as a central mechanism. Neuroimaging studies using positron emission tomography (PET) have shown ipsilateral posterior hypothalamic activation during headache periods in HC patients, a finding shared with other TACs and suggesting a common central generator for this class of headache disorders (May et al., 1999). The trigeminal autonomic reflex arc, mediated through the trigeminal nerve and the sphenopalatine ganglion, is believed to underlie both the pain and the autonomic features of HC. This trigeminal involvement directly explains why peripheral nerve blocks targeting trigeminal sensory branches can provide meaningful pain relief — by interrupting the afferent limb of this arc at the level of the peripheral nerve.

Differential Diagnosis: Distinguishing Hemicrania Continua from Other Headache Types

For practitioners encountering a patient with persistent unilateral headache, the differential diagnosis is broad and must be approached systematically. Key conditions to consider include:

• Chronic migraine: Bilateral or unilateral, episodic or chronic, with nausea, photophobia, phonophobia; responds to triptans and preventive therapies.
• Cluster headache: Strictly unilateral, severe, episodic (cluster periods), with prominent autonomic features; responds to high-flow oxygen and triptans.
• Paroxysmal hemicrania: Similar to HC but episodic, with multiple short-duration attacks per day; also responds to indomethacin.
• Short-lasting unilateral neuralgiform headache attacks (SUNA/SUNHA): Very brief attacks, often with conjunctival injection and tearing.
• Cervicogenic headache: Referred pain from the cervical spine, often associated with restricted neck movement and tenderness; responds to cervical manipulation and nerve blocks.
• Trigeminal neuralgia: Brief, electric shock-like pains in the trigeminal distribution, triggered by touch.
• New daily persistent headache: Continuous headache from onset, without prior episodic pattern.

The indomethacin test — administration of therapeutic indomethacin with complete pain resolution — is the most reliable clinical tool for distinguishing HC from these alternatives. When HC is confirmed, clinicians must address the challenge of long-term management in patients who cannot tolerate or wish to avoid indomethacin, where peripheral nerve block therapy becomes particularly valuable.

Neuroanatomy of the Targeted Peripheral Nerves: The Sensory Map of the Face and Scalp

Overview of Cranial Sensory Innervation

To fully appreciate the rationale and technique of the peripheral nerve block demonstrated in this clinical case, one must first understand the sensory neuroanatomy of the face and scalp. The head is innervated by a rich network of sensory nerve branches, the majority of which are derived from the trigeminal nerve (cranial nerve V) — the largest of the cranial nerves and the principal sensory nerve of the face. Additional contributions come from the cervical plexus, particularly for the scalp and posterior head.

The trigeminal nerve divides into three major branches:

1. Ophthalmic division (V1): Provides sensory innervation to the forehead, scalp anterior to the coronal suture, upper eyelid, nose, and cornea. Its terminal branches include the supratrochlear nerve and the supraorbital nerve, both of which this procedure targets.
2. Maxillary division (V2): Provides sensory innervation to the midface, including the cheek, upper lip, upper teeth, and part of the temple. Its branches include the zygomaticotemporal nerve, also targeted in this procedure.
3. Mandibular division (V3): Provides sensory and motor innervation to the lower face, jaw, anterior ear, and temple. The auriculotemporal nerve — the fourth target in this procedure — is a branch of V3.

Understanding the precise anatomical course, exit points, and distribution of each nerve is essential for accurate needle placement, safe injection technique, and reliable anesthetic effect.

The Supratrochlear Nerve: Anatomy, Function, and Clinical Relevance

The supratrochlear nerve is a terminal branch of the frontal nerve, itself a branch of the ophthalmic division (V1) of the trigeminal nerve. After arising from the frontal nerve within the orbit, the supratrochlear nerve passes medially, exits the orbit just above the trochlea — the fibrocartilaginous pulley through which the superior oblique muscle tendon passes — and emerges at the superomedial aspect of the orbit, typically in the vicinity of the medial canthus.

Once it exits the orbital rim, the supratrochlear nerve courses superiorly along the forehead, providing cutaneous sensory innervation to the medial forehead, the medial upper eyelid, the bridge of the nose, and the medial scalp extending toward the vertex. Its small branches anastomose laterally with those of the supraorbital nerve and medially with those of the infratrochlear nerve, creating an overlapping sensory territory.

Clinically, the supratrochlear nerve frequently contributes to frontal headache and periorbital pain. Patients with supratrochlear neuralgia — a condition characterized by tenderness and pain along the medial forehead and orbit — often respond dramatically to a local nerve block at this site. In the context of HC and other unilateral headache syndromes, tenderness at the supratrochlear exit point indicates that this nerve is carrying nociceptive signals contributing to the overall pain experience. The medial location of this nerve’s exit point, just above the orbital rim near the trochlea, explains why Dr. Jimenez places his thumb against the orbital rim during injection — a critical safety maneuver to prevent the anesthetic solution from tracking inferiorly into the orbital space, where it could potentially cause temporary extraocular muscle paresis or other complications.

The Supraorbital Nerve: Anatomy, Function, and Clinical Relevance

Traveling in parallel with the supratrochlear nerve but positioned more laterally, the supraorbital nerve is the larger and more prominent terminal branch of the frontal nerve. It exits the orbit through the supraorbital foramen or supraorbital notch, a bony landmark palpable along the superior orbital rim at approximately the midpupillary line — roughly one-third of the way from the medial to the lateral aspect of the orbit.

Upon exiting the supraorbital foramen, the supraorbital nerve divides into two main branches: a medial (superficial) branch that supplies the medial forehead and anterior scalp, and a lateral (deep) branch that runs beneath the frontalis and corrugator supercilii muscles to supply the lateral forehead, parietal scalp, and a portion of the frontal scalp extending toward the vertex. This extensive distribution makes the supraorbital nerve a critical conduit for frontal and frontoparietal headache pain.

In clinical practice, supraorbital nerve tenderness is a common physical examination finding in patients with various headache disorders, including migraine, tension-type headache, and HC. The supraorbital nerve has been targeted in multiple interventional pain procedures, including diagnostic nerve blocks, therapeutic blocks with corticosteroids, pulsed radiofrequency treatment, and peripheral nerve stimulation. Its accessible location at the supraorbital notch makes it an ideal target for minimally invasive, office-based interventions.

Pressing over the supraorbital notch—as Dr. Jimenez demonstrates when checking whether the nerve block has been effective—provides immediate clinical feedback. When the patient reports elimination of tenderness at this site following injection, it confirms that the anesthetic has successfully bathed the nerve and interrupted its nociceptive signaling, at least temporarily.

The Zygomaticotemporal Nerve: Anatomy, Function, and Clinical Relevance

The zygomaticotemporal nerve is a branch of the zygomatic nerve, which itself arises from the maxillary division (V2) of the trigeminal nerve. After traversing the pterygopalatine fossa and entering the orbit through the inferior orbital fissure, the zygomatic nerve travels along the lateral orbital wall, divides into the zygomaticofacial and zygomaticotemporal branches, and exits through corresponding foramina in the zygomatic bone.

The zygomaticotemporal nerve exits the skull through a small foramen in the temporal surface of the zygomatic bone, typically located within the temporal fossa just posterior and superior to the lateral orbital rim. It then pierces the temporalis fascia — the deep temporal fascia — to reach the skin of the anterior temporal region, providing sensory innervation to the temple and a portion of the lateral forehead.

This nerve is particularly relevant in temporal headache — a common presentation in patients with HC, migraine, and tension-type headache. The temple is one of the most frequently reported locations of headache pain, and tenderness over the temporalis muscle and the zygomaticotemporal nerve exit point is a consistent clinical finding in patients with active headache. Blocking this nerve interrupts the sensory transmission from the anterior temporal region, contributing to the overall analgesic effect of the multi-site nerve block approach.

An important technical consideration during injection at this site is the proximity of the superficial temporal artery and its branches. The superficial temporal artery courses through the temporal region, and inadvertent intravascular injection of local anesthetic could result in serious systemic toxicity. This is why Dr. Jimenez emphasizes aspiration before injection at this site — drawing back on the syringe plunger to confirm the absence of blood return before depositing the anesthetic solution. This simple but critical step significantly reduces the risk of intravascular injection.

The Auriculotemporal Nerve: Anatomy, Function, and Clinical Relevance

The auriculotemporal nerve is a branch of the mandibular division (V3) of the trigeminal nerve. It has a unique and clinically important anatomy: it originates as two roots that encircle the middle meningeal artery, one on each side, before coalescing into a single trunk. This close relationship with the meningeal vasculature helps explain why meningeal irritation can cause referred temporal pain.

After forming its trunk, the auriculotemporal nerve runs posteriorly, deep to the lateral pterygoid muscle, rounds the neck of the mandibular condyle, and ascends in front of the external ear alongside the superficial temporal artery. As it ascends through the parotid gland and into the temporal region, it gives off several important branches:

• Anterior auricular branches: Sensory innervation to the anterior helix and tragus of the ear
• Branches to the external auditory meatus and tympanic membrane: Sensory innervation to the ear canal
• Superficial temporal branches: Sensory innervation to the temporal scalp
• Articular branches: Sensory innervation to the temporomandibular joint (TMJ)

This last point — the articular innervation to the TMJ — is particularly significant. The auriculotemporal nerve is a primary sensory nerve to the TMJ, and temporomandibular dysfunction (TMD) frequently contributes to or complicates headache disorders, particularly in the temporal region. Patients with HC or chronic migraine often have coexisting TMD, and targeting the auriculotemporal nerve with local anesthetic can address both the primary headache component and the TMJ-related pain component simultaneously.

The preauricular location of the auriculotemporal nerve — where it ascends anterior to the ear alongside the superficial temporal vessels — makes it accessible for nerve block with proper technique. As with the zygomaticotemporal block, aspiration before injection is essential at this site to avoid intravascular injection into the superficial temporal vessels.

Pharmacology of the Local Anesthetic Mixture: Why Lidocaine and Bupivacaine Together

Understanding Local Anesthetic Mechanisms of Action

The local anesthetic mixture used in this peripheral nerve block procedure — a 50/50 combination of 1% lidocaine with epinephrine and bupivacaine — is not arbitrary. This formulation reflects a deliberate pharmacological strategy to optimize the block’s clinical utility by combining the complementary properties of two local anesthetics with different pharmacokinetic profiles.

All local anesthetics work through the same fundamental mechanism: they reversibly block voltage-gated sodium channels (Nav channels) in the neuronal cell membrane, preventing the influx of sodium ions necessary for the generation and propagation of action potentials. When a local anesthetic molecule binds to the sodium channel — specifically, to the intracellular portion of the channel protein, which it accesses by either permeating the membrane in its uncharged (lipid-soluble) form or by entering through the open channel in its charged (water-soluble) form — it stabilizes the channel in its inactivated state, rendering the nerve unable to depolarize and conduct impulses (Butterworth, Strichartz, & Hadley, 2021).

The clinical result is reversible loss of all sensory modalities in the distribution of the blocked nerve — pain, temperature, touch, and pressure — along with potential loss of motor function if motor fibers are affected (though the nerves targeted in this procedure are purely sensory). The duration, potency, and onset of this blockade depend on the local anesthetic’s pharmacokinetic properties, including lipid solubility, protein binding, pKa (which determines the proportion of the drug in the ionized vs. un-ionized form at physiological pH), and intrinsic vasodilatory properties.

Lidocaine: Rapid Onset, Intermediate Duration

Lidocaine (lignocaine) is an amide-type local anesthetic that has been in clinical use since the 1940s and remains one of the most widely used local anesthetics in medicine worldwide. Its pharmacological profile makes it highly suitable for procedural anesthesia requiring rapid onset:

• pKa: 7.9, close to the physiological pH of 7.4, meaning approximately 25% of the drug exists in the un-ionized, lipid-soluble form at physiological pH, enabling relatively rapid membrane penetration
• Onset of action: Rapid — typically 3 to 5 minutes for peripheral nerve blocks
• Duration of action: Intermediate — approximately 60 to 120 minutes for peripheral nerve blocks without epinephrine, extended to 2 to 4 hours with epinephrine
• Protein binding: Approximately 64%, intermediate compared to other local anesthetics
• Lipid solubility: Intermediate

The addition of epinephrine (adrenaline) at a standard concentration of 1:100,000 (0.01 mg/mL) or 1:200,000 to lidocaine serves multiple important purposes:

1. Vasoconstriction: Epinephrine causes local alpha-adrenergic receptor-mediated vasoconstriction, reducing blood flow to the injection site. This slows systemic absorption of lidocaine, keeping it concentrated at the nerve longer and extending the duration of the block.
2. Reduced systemic toxicity: By slowing absorption, epinephrine reduces peak plasma concentrations of lidocaine, decreasing the risk of systemic local anesthetic toxicity (LAST), which can manifest as central nervous system effects (tinnitus, perioral numbness, seizures) and cardiovascular effects (arrhythmias, hypotension) if plasma levels become excessive.
3. Hemostasis: The vasoconstrictive effect also reduces bleeding at the injection site, which is particularly useful near the highly vascular temporal and periorbital regions.
4. Marker of intravascular injection: If the needle is inadvertently placed within a blood vessel and epinephrine is injected intravascularly, it produces an immediate, transient increase in heart rate (by approximately 20 beats per minute), serving as a warning sign (Mulroy, Salinas, & Larkin, 2020).

Bupivacaine: Slower Onset, Extended Duration

Bupivacaine is also an amide-type local anesthetic, structurally related to lidocaine but with markedly different pharmacokinetic properties that give it a distinct and highly valuable clinical role:

• pKa: 8.1, meaning a smaller proportion of the drug is in the un-ionized form at physiological pH compared to lidocaine, resulting in slower membrane penetration and slower onset of action (typically 15 to 30 minutes for peripheral nerve blocks)
• Duration of action: Long — approximately 4 to 12 hours for peripheral nerve blocks, significantly longer than lidocaine
• Protein binding: Approximately 95%, the highest among commonly used local anesthetics, which contributes to its prolonged duration by keeping the drug bound to channel proteins for extended periods
• Lipid solubility: High — approximately 4 times that of lidocaine, enabling deep penetration into the myelin sheath and neuronal membrane

The high lipid solubility and high protein binding of bupivacaine translate directly into its most clinically valuable property: a prolonged duration of nerve blockade that far exceeds that of lidocaine. For the patient in this case — a 71-year-old with a persistent, severe headache — the ability of bupivacaine to maintain nerve blockade for hours to potentially half a day after a single injection is precisely what is needed to “break” the headache — that is, to interrupt the self-sustaining central sensitization cycle that perpetuates the pain beyond the initial peripheral trigger.

The Pharmacological Rationale for the 50/50 Mixture

By combining equal volumes of 1% lidocaine with epinephrine and bupivacaine, the clinician creates a mixture that captures the best properties of both drugs:

• The lidocaine component provides rapid onset of analgesia — within 3 to 5 minutes of injection — so the patient experiences prompt pain relief during the procedure itself and in the early post-procedural period
• The bupivacaine component provides extended duration of analgesia — hours of nerve blockade — ensuring that the analgesic effect outlasts the lidocaine component and continues to work as the lidocaine wears off.
• The epinephrine component extends the effective duration of both anesthetics and reduces systemic absorption and toxicity risk
• The resulting 1 mL volume per site is sufficient to bathe the nerve at each target point without excessive tissue distension or risk of compartment effects

This pharmacological synergy—rapid onset from lidocaine, prolonged duration from bupivacaine, and sustained effect from epinephrine—is why this specific formulation is preferred for peripheral nerve block therapy in headache management. It explains the clinical outcome observed: the patient reports rapid improvement (from 7/10 to 5/10) even before the bupivacaine has fully taken effect, with the expectation of continued and more complete relief as the bupivacaine’s action develops over the subsequent 30 to 60 minutes.

Local Anesthetic Toxicity: Safety Considerations in the Elderly Patient

When performing peripheral nerve blocks in elderly patients, several pharmacokinetic and physiological considerations increase the risk of local anesthetic systemic toxicity (LAST) and must be carefully accounted for:

• Reduced hepatic blood flow and hepatic enzyme activity in older adults slow the hepatic metabolism of amide-type local anesthetics (both lidocaine and bupivacaine are extensively metabolized in the liver), potentially leading to higher and more sustained plasma drug levels after injection
• Reduced plasma protein levels — particularly alpha-1-acid glycoprotein (AAG), the primary plasma protein that binds local anesthetics — increase the free fraction of the drug available for systemic toxic effects.
• Reduced cardiac reserve and increased prevalence of pre-existing cardiac conduction abnormalities increase vulnerability to bupivacaine’s cardiovascular toxicity, which is more severe than that of lidocaine due to bupivacaine’s higher lipid solubility and more avid binding to cardiac sodium channels.
• Reduced central nervous system resilience lowers the seizure threshold for CNS toxicity.y

The 1 mL per site dosing used in this procedure — totaling approximately 4 mL of the mixture for four injection sites — keeps the total dose of each anesthetic well within safe limits even in an elderly patient, provided proper injection technique (including aspiration to exclude intravascular placement) is employed.

The Peripheral Nerve Block Procedure: A Step-by-Step Technical Analysis

Pre-Procedure Assessment and Preparation

The clinical examination that precedes the injection procedure is as important as the injection itself. Dr. Jimenez demonstrates a systematic approach to palpation-based assessment of peripheral nerve exit points, using gentle, firm pressure with the retracted tip of a ballpoint pen—sufficient to elicit tenderness at affected nerve sites without causing unnecessary discomfort or tissue trauma. This approach parallels the diagnostic criteria used in pericranial tenderness assessment for headache disorders, where tenderness at specific pericranial muscle and nerve sites is a validated clinical marker of central sensitization and peripheral nociceptive input (Jensen & Olesen, 1996).

By mapping the exact locations of tenderness before the procedure, Dr. Jimenez accomplishes two critical goals:

1. Diagnostic confirmation: Tenderness at all four nerve exit points on the right side is consistent with widespread trigeminal sensitization in the context of HC, confirming that a peripheral nerve block at these sites is physiologically rational.
2. Procedural targeting: The marked locations serve as precise anatomical landmarks for needle placement, ensuring the anesthetic is deposited at the correct nerve exit points rather than in adjacent tissue where it would have no analgesic effect.

Landmark marking with the retracted ballpoint pen is performed lightly—as Dr. Jimenez explicitly notes—to leave an ink mark without causing pressure-induced skin trauma or a hematoma that could confuse subsequent palpation or distort surface anatomy. The landmarks are then prepped with betadine (povidone-iodine), an antiseptic agent with broad-spectrum antimicrobial activity against bacteria, fungi, and viruses. This skin preparation step is essential to prevent introducing flora into the subcutaneous tissue during needle insertion, which could theoretically cause cellulitis or, in the worst case, deep space infection—particularly relevant in the periorbital region, where such infections can have serious consequences.

Needle Selection: The 30-Gauge Half-Inch Needle

Choosing a 30-gauge, half-inch (13 mm) needle for this procedure is deliberate and clinically important. Needle gauge refers to its outer diameter—a 30-gauge needle has an outer diameter of approximately 0.31 mm (0.012 inches), making it one of the finest gauges used in clinical practice. The advantages of using a 30-gauge needle for facial nerve blocks include:

• Minimal tissue trauma: The extremely small diameter causes minimal tissue disruption during insertion, reducing the risk of hematoma formation in the highly vascular facial tissue
• Reduced pain on insertion: A finer needle causes significantly less discomfort during skin penetration and subcutaneous insertion — a major advantage when injecting sensitive periorbital tissue in a conscious, elderly patient
• Precise delivery: The fine needle allows accurate placement at the identified nerve exit point without the “tunneling” effect of larger needles that can displace tissue and alter the needle tip position relative to the target
• Reduced bleeding risk: The smaller puncture size minimizes the risk of vessel laceration, particularly important near the periorbital vasculature and the superficial temporal vessels

The half-inch (13 mm) length is ideal for reaching the superficial periosteum and nerve exit foramina of the facial skeleton without risking penetration into deeper structures such as the orbital cavity or the intracranial compartment.

The Critical Technique of Periosteal Contact

A key technical detail emphasized in the procedure is the technique of “touching bone”—advancing the needle until the tip contacts the periosteum of the underlying bone at each injection site before depositing the anesthetic. This technique is standard practice for peripheral nerve blocks at bony foramina and serves several important purposes:

1. Precise depth gauge: The periosteum provides a definitive anatomical endpoint for needle advancement, ensuring the needle tip is at the correct depth — at the level of the nerve exit foramen — rather than in superficial subcutaneous tissue (too shallow) or beyond the bone surface (potentially intravascular or in the orbital cavity)
2. Nerve proximity: The nerve exits the skull through or near the bony foramen and lies in intimate proximity to the periosteum at the point of exit. Depositing the anesthetic directly at the periosteal surface maximizes the likelihood of bathing the nerve as it emerges from the foramen, achieving reliable nerve block
3. Mechanical feedback: The tactile sensation of needle-against-bone provides immediate confirmation to the clinician that the needle has reached the correct depth, eliminating guesswork
4. Injection at the foramen: By slightly withdrawing the needle from the periosteum before injecting — “coming off of it,” as Dr. Jimenez describes — the clinician ensures the anesthetic is deposited in the small space adjacent to the nerve exit point, maximizing its spread around the nerve

Aspiration Before Injection: A Non-Negotiable Safety Step

Aspiration — pulling back the syringe plunger before injecting to check for blood return — is a fundamental safety maneuver that must be performed before every injection at every site. Its purpose is straightforward: if the needle tip has been inadvertently advanced into the lumen of a blood vessel (a vascular injury that can occur even with careful technique, particularly near the highly vascular temporal and periorbital regions), aspiration will draw blood into the syringe hub, immediately alerting the clinician to the problem before any anesthetic is injected intravascularly.

Dr. Jimenez explicitly emphasizes aspiration at the zygomaticotemporal and auriculotemporal injection sites, where the proximity of the superficial temporal artery and middle temporal vessels makes intravascular needle placement particularly risky. Intravascular injection of local anesthetic — even in small volumes — can cause systemic toxicity, with neurological manifestations (metallic taste, tinnitus, perioral numbness, visual disturbances, seizures) and potentially fatal cardiovascular effects (arrhythmias, ventricular fibrillation) that are particularly severe with bupivacaine due to its high cardiac sodium channel affinity.

In the periorbital region (supratrochlear and supraorbital injection sites), aspiration is equally important. Still, the additional anatomical concern is the supraorbital artery, a branch of the ophthalmic artery, which accompanies the supraorbital nerve through the supraorbital notch or foramen. Intravascular injection in this region also carries a small but real risk of retrograde tracking of anesthetic into the ophthalmic artery and ultimately the internal carotid artery, which could potentially cause cerebral ischemia in patients with abnormal collateral circulation.

Orbital Rim Protection: The Role of the Thumb Guard

One of the most clinically elegant and practically important technical elements of this procedure is Dr. Jimenez’s use of his thumb against the inferior orbital rim during the supratrochlear and supraorbital injections. This maneuver acts as a physical barrier, preventing the injected local anesthetic solution from tracking inferiorly through the loose periorbital connective tissue and entering the orbital compartment through gaps around the orbital rim.

If local anesthetic enters the orbit in sufficient quantity, it could temporarily paralyze the extraocular muscles (causing diplopia or inability to move the eye), anesthetize the optic nerve (potentially causing transient visual loss), or anesthetize the ciliary ganglion (disrupting pupillary reflexes). While these effects are typically temporary and self-limiting, they can be alarming and potentially dangerous if they occur in a patient who needs to drive or operate machinery shortly after the procedure.

The thumb guard technique — pressing the thumb firmly against the inferior orbital rim medially (for the supratrochlear injection) and at the midpupillary level (for the supraorbital injection) while injecting — effectively redirects the pressure wave of the injected anesthetic away from the orbit and toward the forehead, ensuring that the anesthetic spreads along the nerve in the desired direction without orbital penetration. Dr. Jimenez notes that he can feel the injection pressure against his thumb, which provides real-time tactile confirmation that this protective mechanism is functioning as intended.

Post-Injection Assessment: Confirming Efficacy

The post-injection assessment performed by Dr. Jimenez is a model of clinical efficiency and direct outcome measurement. Within minutes of completing all four injections, he re-examines the patient using the same systematic palpation approach used during the pre-injection assessment:

• He presses over each nerve exit point and asks the patient whether the tenderness that was present before the injection is still present
• The patient confirms that all four previously tender sites are now pain-free on palpation, indicating successful nerve block at all targets.
• He asks the patient to rate her headache on the numeric pain rating scale (NRS), and she reports improvement from 7/10 pre-injection to 5/10 immediately post-injection
• He notes that the block is still “very early in the process” and anticipates continued improvement over the next 30 to 60 minutes as the full effect of the bupivacaine develops.s

This structured pre- and post-procedure pain assessment using the NRS is consistent with evidence-based clinical practice standards for pain measurement and outcome documentation (Dansie & Turk, 2013). The numeric rating scale has been extensively validated as a reliab, nd sensitive measure of pain intensity, and its use in this context provides clinical feedback to guide treatment decisions and documentable outcome data for the medical record.

The Evidence Base for Peripheral Nerve Blocks in Headache Management

Historical Perspective and Evolution of Nerve Block Therapy

Peripheral nerve blocks for headache management have a long history in clinical medicine, dating back to the early 20th century, when neurologists first recognized that local anesthetic infiltration around pericranial nerves could relieve patients with intractable head pain. However, only in the past two to three decades has this approach undergone rigorous scientific scrutiny, and a robust body of evidence-based literature has accumulated demonstrating its efficacy, safety, and mechanism of action.

Several parallel developments have driven the evolution of nerve block therapy for headache: a better understanding of the peripheral and central mechanisms of headache pain, the development of safer and more effective local anesthetic formulations, refinements in injection technique based on detailed anatomical studies, and the growing recognition that many headache disorders — particularly those with a strong peripheral sensory component — are amenable to interventional approaches that complement or replace systemic pharmacotherapy.

Randomized Controlled Trials and Systematic Reviews

The literature supporting peripheral nerve blocks for headache is now substantial, with numerous randomized controlled trials (RCTs), prospective cohort studies, and systematic reviews demonstrating clinically meaningful benefits across multiple headache subtypes.

Supraorbital and supratrochlear nerve blocks have been studied most extensively for migraine and tension-type headache. A landmark randomized controlled trial by Inan, Inan, Karadas, and colleagues (2015) compared supraorbital nerve block (using lidocaine and methylprednisolone) to oral sumatriptan for the treatment of acute migraine attacks and found that the nerve block produced faster and more complete pain relief than the oral triptan at 15, 30, and 60 minutes, with a significantly higher proportion of patients achieving complete pain freedom at 2 hours. These findings are particularly meaningful for patients who cannot tolerate oral medications or who have inadequate responses to standard pharmacotherapy.

A systematic review and meta-analysis by Dach, Eckeli, Ferreira Kdos, and Speciali (2015) examined the evidence for peripheral nerve blocks in the prevention and treatment of migraine, analyzing data from multiple RCTs, and concluded that nerve blocks produced significant reductions in headache frequency, intensity, and duration compared to placebo, with an excellent safety profile.

For hemicrania continua specifically — the diagnosis in the patient presented in this case — evidence for peripheral nerve blocks is more limited but growing. Case series and observational studies have documented substantial pain relief following supraorbital, supratrochlear, and greater occipital nerve blocks in HC patients who either cannot tolerate indomethacin or have incomplete responses to it (Antonaci, Sjaastad, & Fredriksen, 2003). The physiological rationale is compelling: if peripheral trigeminal nociceptive input is contributing to the maintenance of central sensitization in HC — as the neuroimaging evidence suggests — then interrupting this input with peripheral nerve block could break the sensitization cycle and provide lasting relief even after the local anesthetic wears off.

The Mechanism of Lasting Pain Relief: Peripheral Block Breaking Central Sensitization

One of the most scientifically fascinating aspects of peripheral nerve block therapy for headache is that the analgesic effect often outlasts the local anesthetic by many hours, days, or even weeks. This phenomenon — in which a temporary chemical nerve block produces pain relief that persists long after the drug has metabolized and the nerve has recovered its normal function — cannot be explained by the pharmacological duration of the anesthetic alone and requires a deeper mechanistic understanding.

The explanation lies in the concept of central sensitization — a state of heightened responsiveness in the central nervous system (CNS) that develops in response to prolonged peripheral nociceptive input and is a key pathophysiological mechanism in chronic pain disorders, including chronic headache. Central sensitization involves:

• Wind-up: Progressive amplification of spinal and brainstem dorsal horn neuron firing in response to repeated C-fiber input
• Long-term potentiation (LTP): Synaptic strengthening at trigeminal dorsal horn synapses that persists beyond the acute pain episode
• Glial activation: Activation of microglia and astrocytes in the trigeminal nucleus caudalis that sustains neuroinflammation and amplifies pain signaling.
• Reduced descending inhibition: Diminished activity of the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM) descending pain inhibitory pathways

When a peripheral nerve is blocked with local anesthetic, the complete cessation of nociceptive input from that nerve — even temporarily — allows the central sensitization state to “reset” or at least partially resolve. Stopping peripheral drive reduces ongoing stimulation of central sensitization mechanisms, allows descending inhibitory pathways to reassert control, and breaks the positive feedback loop that perpetuates the headache. When the nerve block wears off and normal nerve function returns, central sensitization has diminished, and the patient experiences less pain even from the same peripheral nociceptive input that previously produced a severe headache (Woolf, 2011).

This mechanism explains the clinical observation in the current case: the expectation that the headache will not only improve during the procedure but will “continue to work for hours afterward, and hopefully break this headache completely” — a statement that reflects a sophisticated mechanistic understanding of how nerve blocks produce their therapeutic effects in chronic headache disorders.

Greater Occipital Nerve Blocks: Complementary Evidence

While the four nerves targeted in this procedure are all anterior and lateral branches of the trigeminal nerve (ophthalmic and mandibular divisions), a complementary body of evidence supports the use of greater occipital nerve (GON) blocks for a variety of headache disorders. The GON, arising from the C2 dorsal root, provides sensory innervation to the posterior scalp from the occiput to the vertex. GON blocks have been studied extensively in migraine, cluster headache, HC, and cervicogenic headache, with multiple RCTs demonstrating significant reductions in headache frequency and intensity (Blumenfeld, Ashkenazi, Napchan, & Grosberg, 2013).

The fact that a posterior cervical nerve block can reduce pain from anterior and temporal headache distributions reflects the functional connectivity between the trigeminocervical complex — the region of the brainstem and upper cervical spinal cord where trigeminal and cervical sensory inputs converge — and the central pain processing systems. This convergence is the anatomical basis for cervicogenic headache, in which pain from the cervical spine is referred to the head, and for the general principle that treating the cervical component of headache disorders can reduce overall headache burden even when the primary pain is perceived in the frontal or temporal regions.

This cervicogenic-trigeminal connection is of particular relevance to the chiropractic component of integrative headache management, as we will explore in detail below.

Integrative Chiropractic Care in Headache Management: Dr. Jimenez’s Clinical Approach

The Role of Chiropractic Manipulation in Headache Disorders

Chiropractic care occupies a uniquely powerful position in the integrative management of headache disorders, particularly those with a cervicogenic component or those in which cervical spinal dysfunction contributes to or perpetuates the pain. At Injury Medical Clinic PA in El Paso, Texas, Dr. Alexander Jimenez brings his extensive expertise as a Doctor of Chiropractic (DC) along with his advanced training as an Advanced Practice Registered Nurse (APRN), Family Nurse Practitioner (FNP-BC), and advanced certifications in Functional Medicine (CFMP, IFMCP), Acupuncture and Traditional Naturopathy (ATN), and Chiropractic Sports and Trauma (CCST) to bear in developing individualized, multimodal treatment plans for patients with complex headache disorders.

The foundational premise of chiropractic manipulation in headache management is that vertebral subluxation — or more broadly, segmental spinal dysfunction — in the cervical spine can generate afferent nociceptive input that contributes to headache through the trigeminocervical complex. When cervical joints, muscles, ligaments, and associated structures are mechanically dysfunctional — restricted in their normal range of motion, inflamed, or generating abnormal proprioceptive and nociceptive signals — this creates a persistent peripheral drive to the trigeminocervical complex that contributes to central sensitization and headache maintenance.

Cervical spinal manipulation — the application of a high-velocity, low-amplitude (HVLA) thrust to a specific spinal segment — produces its therapeutic effects through multiple mechanisms:

1. Joint cavitation and pain relief: The characteristic audible “crack” associated with HVLA manipulation reflects the formation and collapse of gas bubbles within the synovial fluid of the zygapophysial (facet) joint — a phenomenon called cavitation. This produces immediate mechanoreceptor stimulation that activates large-diameter A? sensory fibers, which at the spinal cord level inhibit pain signal transmission from small-diameter A? and C fibers through segmental inhibition mechanisms — the neurophysiological basis of the gate control theory of pain (Melzack & Wall, 1965).
2. Neurophysiological effects on pain processing: HVLA manipulation has been shown to produce immediate changes in pain pressure thresholds not only at the manipulated segment but also at remote sites, including the trigeminal nerve distribution, suggesting that manipulation activates supraspinal pain inhibitory systems — including descending pathways from the periaqueductal gray and dorsal raphe nucleus — that broadly modulate pain processing (Coronado, Gay, Bialosky, & George, 2012).
3. Muscle reflex inhibition: Manipulation reduces hypertonic muscle activity in the paraspinal muscles adjacent to the treated segment, breaking the cycle of muscle tension and joint compression. more muscle tension that perpetuates segmental dysfunction and its associated pain referral patterns.
4. Restoration of joint mobility: Manipulation restores normal articular motion to restricted spinal segments, reducing abnormal mechanoreceptor firing patterns generated by joints stuck in a restricted range of motion and normalizing afferent input to the central nervous system.
5. Anti-inflammatory effects: Emerging evidence suggests that spinal manipulation produces local anti-inflammatory effects in manipulated tissues, including reductions in pro-inflammatory cytokines (such as TNF-?, IL-1, and IL-6) in the surrounding tissue fluid, contributing to tissue healing and pain reduction (Teodorczyk-Injeyan, Injeyan, & Ruegg, 2006).

Evidence Supporting Chiropractic Manipulation for Headache

The evidence base supporting chiropractic spinal manipulation for headache — particularly cervicogenic headache and migraine — has grown substantially over the past two decades.

A landmark systematic review and meta-analysis conducted by Bronfort, Haas, Evans, Leininger, and Triano (2010) for the RAND Corporation analyzed the evidence for chiropractic treatment of various conditions. They found evidence of benefit for spinal manipulation in treating cervicogenic headache and migraine, with effect sizes comparable to those of commonly used preventive pharmacological agents.

A high-quality randomized controlled trial by Tuchin, Pollard, and Bonello (2000), published in the Journal of Manipulative and Physiological Therapeutics, found that cervical spinal manipulation significantly reduced migraine frequency, duration, and medication use compared with a control group, with clinical improvements maintained at the 4-week post-treatment follow-up. The effect sizes observed in this trial were comparable to those of amitriptyline, a standard preventive migraine medication, suggesting that spinal manipulation is a clinically meaningful therapeutic option for migraine prevention.

For cervicogenic headache — a headache type characterized by pain referred from the cervical spine that closely resembles the cervicogenic component of many headache presentations, including HC complicated by cervical dysfunction — a randomized controlled trial by Nilsson, Christensen, and Hartvigsen (1997) found that spinal manipulation produced significant reductions in headache frequency and use of analgesics compared to a control group receiving soft tissue massage only. The cervicogenic headache reduction with manipulation persisted at both short-term (immediate post-treatment) and long-term (follow-up at several weeks) time points.

The Trigeminocervical Complex: The Neuroanatomical Bridge Between the Neck and the Head

The trigeminocervical complex (TCC) is a region of the caudal brainstem and upper cervical spinal cord — extending from the trigeminal nucleus caudalis (located in the medulla oblongata) through the dorsal horns of C1, C2, and C3 — where trigeminal sensory afferents and upper cervical sensory afferents converge on common second-order neurons.

This anatomical convergence is not merely an abstract neuroanatomical curiosity; it has profound clinical implications for understanding why:

• Cervical spine problems can cause headache felt in the forehead, temple, or orbit (cervicogenic headache)
• Headache treatments targeting one division of the TCC can reduce pain perceived in anatomically distant regions
• Both cervical manipulation (targeting cervical afferents) and peripheral trigeminal nerve blocks (targeting trigeminal afferents) can each reduce the overall sensitization state of the TCC, producing headache relief

The convergence works as follows: upper cervical afferents from C1, C2, and C3 nerve roots (carrying pain signals from the suboccipital muscles, cervical facet joints, atlantoaxial joint, and cervical intervertebral discs) synapse on second-order neurons in the trigeminal nucleus caudalis alongside trigeminal afferents from the face and scalp. Because the brain uses the same second-order neurons to process both sets of input, it can misattribute the source of activation — perceiving cervical joint pain as frontal or temporal headache, and vice versa. This is precisely the neuroanatomical basis of referred pain from the cervical spine to the head (Bogduk, 2001).

When Dr. Jimenez applies cervical manipulation as part of the integrative management plan for a patient with HC, he is directly targeting this trigeminocervical convergence — reducing the cervical afferent input that is simultaneously driving both the neck symptoms (if present) and contributing to the central sensitization state in the TCC that amplifies the trigeminal headache component. When manipulation normalizes this cervical input, the burden on the TCC decreases, and the threshold for headache generation rises—reducing both headache frequency and intensity.

Soft Tissue Therapy and Myofascial Release in Headache Management

Alongside spinal manipulation, soft tissue therapies—including myofascial release, trigger point therapy, deep tissue massage, instrument-assisted soft tissue mobilization (IASTM), and active release techniques (ART)—play an essential complementary role in chiropractic headache management. These techniques address the muscular component of headache pathophysiology, which is often underestimated in cranial muscles — including the temporalis, sternocleidomastoid (SCM), upper trapezius, suboccipital group (rectus capitis posterior major and minor, obliquus capitis superior and inferior), semispinalis capitis, and splenius capitis — which are frequent sites of active myofascial trigger points in headache patients. A trigger point is a hypersensitive nodule within a taut band of skeletal muscle that produces characteristic referred pain patterns when compressed or activated. Critically, referred pain from cervical and cranial muscles reproduces the headache pain the patient feels. For example, trigger points in the SCM refer pain to the frontal region and orbit, trigger points in the upper trapezius refer pain to the temple, and trigger points in the suboccipital muscles refer pain to the posterior and temporal head.

The mechanism of myofascial trigger point pain involves localized muscle hypoxia and metabolic distress within the taut band, which creates a microenvironment of acidic pH, elevated substance P, bradykinin, serotonin, and other algogenic substances that directly sensitize the nociceptive free nerve endings (type III and IV muscle afferents) within the trigger point. These sensitized afferents fire continuously, contributing to the peripheral nociceptive drive that sustains central sensitization in the TCC and perpetuates the headache cycle.

Myofascial release and trigger point therapy applied to the suboccipital, cervical, and cranial muscles directly deactivate these trigger points by mechanically disrupting the taut band, restoring normal muscle metabolism, flushing out algogenic substances, and normalizing the firing pattern of the associated nociceptive afferents. Clinical studies have consistently demonstrated that trigger point therapy for headache — particularly tension-type headache and cervicogenic headache — produces significant reductions in headache frequency, intensity, and pericranial tenderness, often with outcomes comparable to or better than those achieved with pharmacological preventive therapies (Bodes-Pardo et al., 2013).

Cervical Decompression and Traction Therapy

For patients with cervical disc pathology, facet joint osteoarthritis, foraminal stenosis, or other structural cervical conditions that compress or irritate cervical nerve roots, cervical traction — either manual or mechanical — can provide significant relief by reducing compressive forces on the compressed neural and vascular structures, allowing inflammation and edema to resolve and restoring normal nerve root function.

In the context of headache management, cervical traction is particularly useful when C2 or C3 nerve root compression contributes to the headache syndrome — as these are the cervical nerve roots whose sensory territory converges most extensively with trigeminal afferents in the TCC. By relieving compression on these roots, traction reduces the aberrant nociceptive input driving central sensitization and can meaningfully reduce headache.

At Injury Medical Clinic PA, the integration of chiropractic manipulation with cervical traction, soft tissue therapy, and — when indicated — peripheral nerve block injections represents a comprehensive, mechanistically rational approach to headache management that addresses the disorder at multiple levels simultaneously: peripheral nociceptive input (manipulation, traction, trigger point therapy, nerve blocks), central sensitization (all of the above, plus functional medicine and nutritional strategies), and the structural and biomechanical factors that perpetuate the condition over time.

Functional Medicine Approaches to Chronic Headache: Addressing Root Causes

The Functional Medicine Model Applied to Headache

Functional medicine represents a fundamental shift in how clinicians approach chronic disease—including chronic headache. Rather than simply managing symptoms with pharmacological agents, functional medicine seeks to identify and address the underlying biological, environmental, and lifestyle factors that drive the disease process. For patients with refractory headache disorders such as HC, this approach often uncovers and addresses contributors that conventional pharmacological management does not address, leading to more durable and comprehensive relief.

Dr. Jimenez’s training and certification in Functional Medicine (CFMP, IFMCP) position him to integrate this paradigm into headache management in ways that go far beyond conventional chiropractic or medical care. The functional medicine approach to headache involves a thorough assessment of:

1. Nutritional status and deficiencies: Several specific nutrient deficiencies have been implicated in headache pathophysiology
2. Hormonal imbalances: Particularly estrogen, testosterone, cortisol, and thyroid hormones
3. Inflammatory status: Systemic low-grade inflammation drives central sensitization and headache maintenance
4. Gut microbiome health: The gut-brain axis and its role in headache
5. Mitochondrial function: Energy metabolism and headache threshold
6. Environmental toxin exposure: Heavy metals and other neurotoxins
7. Sleep quality and circadian rhythm disruption: A bidirectional relationship with headache
8. Psychological stress and trauma: The neuroimmune effects of chronic stress

Magnesium Deficiency and Headache: A Critical Relationship

Magnesium is a critical cofactor in over 300 enzymatic reactions in the human body, including many that are directly relevant to headache physiology. Its role in neuronal excitability is particularly important: magnesium ions act as physiological blockers of N-methyl-D-aspartate (NMDA) receptors — the glutamate receptors that are the primary molecular substrate of central sensitization, wind-up, and long-term potentiation at pain-signaling synapses in the trigeminal nucleus caudalis and dorsal horn. When magnesium levels are adequate, magnesium ions physically block the NMDA receptor channel at normal resting membrane potentials, preventing excessive calcium entry that would lead to receptor over-activation and sensitization. When magnesium is deficient, this NMDA blocking effect is reduced, lowering the threshold for central sensitization and rendering the pain processing system hyperexcitable (Maier et al., 2022).

Multiple studies have documented intracellular magnesium deficiency in patients with migraine and other chronic headache disorders, even when serum magnesium levels appear normal — a finding that underscores the importance of measuring red blood cell (RBC) magnesium or ionized magnesium rather than relying on standard serum magnesium, which reflects only a small fraction of total body magnesium. A meta-analysis by Shaik and Bhatt (2021) found that oral magnesium supplementation significantly reduced migraine attack frequency and intensity compared to placebo, with a favorable safety profile even at doses of 400–600 mg per day.

In the functional medicine framework, ensuring magnesium repletion is therefore a foundational element of headache management — not as a replacement for other therapies but as a mechanism to restore the physiological conditions under which other treatments (nerve blocks, manipulation, behavioral interventions) can achieve their maximum efficacy.

Vitamin D3 and K2: Neuroimmune Modulation in Headache

Vitamin D3 (cholecalciferol) and its active metabolite 1,25-dihydroxyvitamin D3 (calcitriol) exert profound effects on the neuroimmune system that are directly relevant to headache pathophysiology. Vitamin D receptors (VDRs) are expressed throughout the brain, including in regions implicated in headache processing such as the hypothalamus, the periaqueductal gray (PAG), and the trigeminal ganglion. Through these receptors, active vitamin D modulates:

• Neuroinflammation: Vitamin D suppresses the production of pro-inflammatory cytokines (TNF-?, IL-6, IIL-1? by microglia and immune cells in the CNS, reducing neuroinflammatory burden that contributes to central sensitization
• Serotonin synthesis: Vitamin D upregulates the enzyme tryptophan hydroxylase 2 (TPH2), the rate-limiting enzyme in serotonin synthesis in the brain, increasing serotonin availability in the CNS — relevant because serotonin is a key neurotransmitter in descending pain inhibitory pathways
• Calcitonin gene-related peptide (CGRP) modulation: Emerging evidence suggests that vitamin D may modulate the expression and release of CGRP, a neuropeptide that is central to migraine pathophysiology and is the target of the newest class of migraine-specific medications (CGRP monoclonal antibodies)

A systematic review by de Magalhães, Leite, and Peres (2022) found consistent associations between vitamin D insufficiency (serum 25-hydroxyvitamin D levels below 30 ng/mL) and increased headache frequency, severity, and chronification risk across multiple headache types.

Vitamin K2 (menaquinone) is co-administered with vitamin D3 in functional medicine practice because of its role in directing calcium to appropriate tissue compartments — specifically, K2 activates matrix Gla protein (MGP) and osteocalcin, which prevent calcium deposition in soft tissues (arteries, muscles, joints) while promoting its incorporation into bone. This is particularly relevant because high-dose vitamin D3 supplementation without adequate K2 can potentially increase soft tissue calcification risk in susceptible patients.

Omega-3 Fatty Acids: Anti-Inflammatory Neurochemistry

Omega-3 polyunsaturated fatty acids (PUFAs) — particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) — are essential structural components of neuronal cell membranes and precursors to a family of potent anti-inflammatory and pro-resolving lipid mediators known as resolvins, protectins, and maresins. These mediators, produced by the enzymatic processing of EPA and DHA, actively resolve neuroinflammation in the CNS by:

• Inhibiting NF-?B signaling, the master transcription factor driving pro-inflammatory gene expression
• Reducing microglial activation and pro-inflammatory cytokine production
• Promoting the clearance of cellular debris and inflammatory mediators from neural tissue
• Reducing the synthesis of pro-inflammatory eicosanoids (prostaglandins, thromboxanes) from the competing omega-6 substrate arachidonic acid

The Western diet — typically characterized by an omega-6:omega-3 ratio of 15:1 to 20:1 or higher, compared to the evolutionarily appropriate ratio of approximately 4:1 to 1:1 — creates a pro-inflammatory biochemical environment that promotes neuroinflammation, central sensitization, and headache chronification. Correcting this imbalance through dietary modification and high-quality omega-3 supplementation is a clinically meaningful functional medicine intervention for headache patients.

A randomized controlled trial by Ramsden and colleagues (2013), published in the BMJ, found that a high omega-3, low omega-6 dietary intervention produced a 30% reduction in total headache hours per day and a 40% reduction in headache intensity in patients with chronic daily headache — effect sizes that rival those of preventive pharmacological therapies.

Riboflavin (Vitamin B2) and Mitochondrial Function in Headache

Riboflavin (vitamin B2) is an essential cofactor in mitochondrial energy metabolism, functioning as a precursor to flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) — critical coenzymes in the electron transport chain (complexes I and II) that drives ATP synthesis in mitochondria. The relevance of mitochondrial function to headache — particularly migraine — is supported by substantial evidence:

• Neuroimaging studies using phosphorus magnetic resonance spectroscopy (31P-MRS) have documented reduced brain mitochondrial ATP production in migraine patients between attacks, suggesting a state of chronic mitochondrial insufficiency that lowers the threshold for headache initiation.
• Genetic studies have identified mitochondrial DNA mutations in patients with mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) — a mitochondrial disease in which migraine-like headaches are a cardinal feature.e
• The spreading cortical depression (CSD) that underlies migraine aura — and may also be relevant to HC — requires massive, synchronized neuronal depolarization that is highly energy-intensive and may be facilitated by states of mitochondrial insufficiency.cy

Multiple RCTs have studied riboflavin supplementation at 400 mg per day for migraine prevention, and a meta-analysis by Thompson and Wolf (2017) showed significant reductions in migraine attack frequency compared with placebo, supporting its use as a first-line preventive supplement for patients with frequent migraine. Given the mitochondrial mechanisms shared between migraine and HC, riboflavin supplementation is a rational functional medicine intervention for HC patients as well.

Coenzyme Q10 and the Mitochondrial Hypothesis of Headache

Coenzyme Q10 (CoQ10, ubiquinone) is a lipid-soluble molecule that serves as an essential electron carrier in the mitochondrial electron transport chain, shuttling electrons between complex I/II and complex III while also functioning as a potent membrane-bound antioxidant that protects mitochondrial membranes and mtDNA from oxidative damage. Like riboflavin, CoQ10 is relevant to headache through the mitochondrial energy hypothesis:

• Plasma and blood cell CoQ10 deficiency has been documented in a significant proportion of migraine patients, and the degree of deficiency correlates inversely with headache frequency.RCTs show that
• CoQ10 supplementation at 150–300 mg per day reduces migraine attack frequency by about 50% in deficient patients, meeting the accepted standard for a clinically meaningful preventive therapy.
• CoQ10 levels decline with age — particularly relevant for the 71-year-old patient in this case, in whom age-related mitochondrial dysfunction may be contributing to her headache burden

Hormonal Influences on Headache: Estrogen, Cortisol, and Thyroid Function

Hormonal factors are among the most powerful modulators of headache threshold and frequency in women, and their assessment and management are a core component of the functional medicine approach to headache in female patients. The 71-year-old woman in this clinical case is postmenopausal, and the hormonal changes associated with menopause — particularly the decline in estrogen — have profound implications for headache biology:

Estrogen modulates headache through multiple mechanisms:

• Serotonin system regulation: Estrogen upregulates serotonin transporter (SERT) and receptor expression in the brainstem, increasing serotonin availability in descending pain-inhibitory pathways. The estrogen withdrawal that accompanies menstrual cycles (in premenopausal women) or menopause (in postmenopausal women) reduces serotonin activity, lowering the threshold for headache initiation.
• CGRP modulation: Estrogen modulates CGRP expression and release from trigeminal neurons — CGRP levels increase during estrogen withdrawal, contributing to vasodilation and neuroinflammation in the meninges
• Central sensitization threshold: Estrogen has antinociceptive effects in the CNS through its actions on NMDA receptors and other pain-modulating systems. Estrogen deficiency reduces these antinociceptive effects, raising susceptibility to central sensitization.n

Cortisol — the primary glucocorticoid stress hormone produced by the adrenal cortex — has a complex, dose-dependent relationship with headache and pain. Acute cortisol elevation during the early stress response has anti-inflammatory effects through glucocorticoid receptor-mediated suppression of NF-?B. However, chronic cortisol elevation—the pattern seen in patients with chronic psychological stress, HPA axis dysregulation, or poor stress coping—produces neuroinflammation, hippocampal atrophy, increased CRH (corticotropin-releasing hormone) release, and heightened nociceptive sensitivity through mechanisms that include upregulation of the CGRP system and reduced endogenous opioid tone.

Measuring and addressing HPA axis dysregulation — through salivary cortisol profiles, adrenal support strategies, stress reduction interventions, and adaptogenic supplements — is therefore a meaningful component of functional medicine headache management, particularly in patients with high stress loads, trauma histories, or evidence of adrenal fatigue.

Thyroid hormones — particularly T3 (triiodothyronine) and T4 (thyroxine) — regulate global CNS metabolism and are essential for normal mitochondrial function. Hypothyroidism (even in its subclinical form, defined as elevated TSH with normal T4) is associated with increased headache frequency, migraine exacerbation, and generalized pain sensitivity through mechanisms that include reduced ATP production, altered serotonin metabolism, and decreased pain inhibitory capacity. Assessing and managing thyroid function is a standard component of the functional medicine headache workup.

Dr. Maria Guadalupe Cardenas, MD: Medical Direction and Collaborative Internal Medicine Care

The Medical Director’s Role in an Integrative Injury Care Practice

At Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, the clinical partnership between Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, and Dr. Maria Guadalupe Cardenas, MD (NPI #1164426749, Texas MD License #J2933) exemplifies the most effective model of integrative, multidisciplinary healthcare — one in which the complementary expertise of a chiropractor/functional medicine practitioner and an internal medicine physician are combined to provide comprehensive, patient-centered care that neither discipline could fully deliver alone.

Dr. Cardenas is Board Certified in Internal Medicine and brings more than 40 years of clinical experience as an internist to her role as Medical Director and Collaborative Physician at the practice. Her decades of experience encompass the full breadth of internal medicine — the diagnosis and management of complex medical conditions affecting the cardiovascular, pulmonary, gastrointestinal, endocrine, renal, hematological, and neurological systems — making her an invaluable resource for the comprehensive evaluation and medical management of patients with multi-system complexity, which is the norm rather than the exception in a practice treating patients with chronic pain, injury-related conditions, and neurological disorders.

As Medical Director, Dr. Cardenas provides physician oversight of the practice’s clinical operations, ensuring all services meet the highest standards of medical safety and quality. This role is not merely administrative: in a clinical setting where interventional procedures (such as the peripheral nerve blocks described in this post), diagnostic imaging, prescription medications, and complex rehabilitative protocols are employed, having a physician with the depth and breadth of an experienced internist as Medical Director ensures that every patient’s care is grounded in comprehensive medical evaluation and that potential medical complications — drug interactions, contraindications to procedures, previously undiagnosed systemic conditions that could complicate care — are identified and managed appropriately.

As Collaborative Physician, Dr. Cardenas works directly alongside Dr. Jimenez to evaluate and manage specific patients—particularly those with complex medical comorbidities, those requiring prescription medications within the internist’s scope of practice, and those for whom a formal medical diagnosis is required to guide or justify specific treatments. In Texas, the collaborative practice model between a physician and an advanced practice registered nurse (APRN) — which Dr. Jimenez is, holding both DC and APRN/FNP-BC credentials — requires a formal collaborative practice agreement specifying the terms of physician oversight and consultation. Dr. Cardenas fulfills this requirement, enabling Dr. Jimenez to practice to the full extent of his APRN licensure within the structured oversight framework that Texas law requires.

The Clinical Significance of 40 Years of Internal Medicine Experience

The depth of clinical experience that Dr. Cardenas brings to the practice cannot be overstated. With over four decades of practice in internal medicine, she has encountered and managed the full spectrum of human disease — from acute medical emergencies to chronic complex conditions, from straightforward presentations to diagnostically challenging cases that would confound less experienced clinicians. This depth of experience provides several specific benefits to the integrative practice:

Pattern Recognition at Its Highest Level: In medicine, nothing replaces the pattern recognition that develops over decades of clinical practice. An experienced internist with 40 years of practice has personally evaluated and managed tens of thousands of patients, building a mental library of clinical presentations, atypical manifestations, rare diagnoses, and subtle warning signs that enables diagnostic acuity no amount of textbook knowledge can fully replicate. For patients presenting to an injury or pain clinic, this level of pattern recognition is invaluable for identifying “red flag” symptoms — those features that suggest a serious underlying medical condition requiring urgent evaluation and management, rather than or in addition to the musculoskeletal or neurological condition driving the patient’s chief complaint.

In the context of headache management, for example, Dr. Cardenas’s experience enables her to quickly distinguish primary headache disorders (benign, albeit disabling, conditions like HC and migraine) from secondary headaches caused by potentially life-threatening conditions such as subarachnoid hemorrhage (the “thunderclap headache” of a ruptured aneurysm), cerebral venous sinus thrombosis, meningitis or encephalitis, hypertensive emergency, intracranial mass lesion, or giant cell arteritis (temporal arteritis) — a particularly important consideration in an elderly patient presenting with new or worsening unilateral headache, since giant cell arteritis, which can cause blindness and stroke if untreated, is a disease that predominantly affects individuals over age 50.

Medical Comorbidity Management: Patients with chronic pain and headache disorders frequently have significant medical comorbidities — hypertension, diabetes mellitus, coronary artery disease, chronic kidney disease, autoimmune conditions, psychiatric disorders — that affect both the choice of treatments for the primary condition and the patient’s overall health and quality of life. Managing these comorbidities optimally requires an experienced internist’s expertise. Dr. Cardenas’s medical direction ensures that patients at the practice receive not only excellent pain and rehabilitation care but also appropriate medical management of their underlying chronic conditions, reducing the burden of comorbid disease on their overall pain experience and functional capacity.

Medication Management and Pharmacovigilance: The management of chronic headache often requires prescription medications — preventive agents (antidepressants, anticonvulsants, beta-blockers, CGRP monoclonal antibodies), acute treatment agents (triptans, ergotamines, opioids in carefully selected cases), and adjunctive medications (muscle relaxants, benzodiazepines, sleep aids). Many of these medications have significant drug-drug interaction profiles and contraindications based on medical comorbidities. Dr. Cardenas’s internal medicine expertise ensures medication choices are safe, appropriate, and optimally managed for each patient’s medical profile.

Diagnostic Workup Oversight: Appropriate diagnostic evaluation for headache — including neuroimaging (MRI, CT), laboratory investigations (complete blood count, inflammatory markers, metabolic panel, hormonal assays), and specialty referrals (neurology, ophthalmology, rheumatology) — is guided and coordinated under Dr. Cardenas’s medical direction, ensuring that the diagnostic workup is both comprehensive and efficient.

The Multidisciplinary Care Model: Integration in Practice

The clinical model at Injury Medical Clinic PA is a textbook example of a well-functioning multidisciplinary care practice that integrates:

• Chiropractic care (Dr. Jimenez, DC): Spinal manipulation, soft tissue therapy, instrument-assisted mobilization, cervical traction, rehabilitation exercise, postural correction
• Functional medicine (Dr. Jimenez, CFMP, IFMCP): Comprehensive nutritional assessment, laboratory-guided supplementation, lifestyle medicine, gut health optimization, hormonal evaluation
• Advanced practice nursing (Dr. Jimenez, APRN, FNP-BC): Patient assessment, diagnosis, prescription medication management (within the collaborative practice agreement), patient education
• Peripheral nerve interventions (Dr. Jimenez): Nerve block injections for headache and pain management
• Internal medicine (Dr. Cardenas, MD): Medical direction, complex medical diagnosis, comorbidity management, prescription oversight, specialist coordination
• Personal injury care: Comprehensive management of injuries sustained in motor vehicle accidents, workplace injuries, slip-and-fall incidents, and sports injuries
• Rehabilitation: Supervised exercise therapy, functional rehabilitation, work conditioning, return-to-activity progression

This integrative model recognizes a fundamental truth of clinical medicine: chronic pain and headache disorders are multifactorial, arising from interactions among biomechanical, neurological, biochemical, hormonal, psychological, and social factors. No single discipline — no matter how skilled its practitioners — can fully address all of these dimensions alone. Only through intentional, coordinated collaboration across disciplines—each contributing unique expertise while communicating and collaborating with colleagues—can patients with complex conditions receive the comprehensive care they need to achieve durable recovery and quality of life.

Personal Injury Care and the Trauma-Headache Relationship

Post-Traumatic Headache: A Common and Underdiagnosed Condition

The ICHD-3 defines post-traumatic headache (PTH) as headache arising within seven days of head injury or trauma to the neck, regaining consciousness after head injury, or discontinuation of post-traumatic amnesia. PTH is one of the most common sequelae of traumatic brain injury (TBI) and whiplash-associated disorder (WAD), affecting an estimated 30–90% of patients after mild TBI or concussion and up to 50% of patients after more severe head injuries.

The mechanisms by which trauma triggers headache are multiple and overlapping:

1. Direct neuronal injury: Traumatic axonal injury at the time of impact disrupts neuronal function and triggers neuroinflammatory cascades that sensitize pain-processing pathways
2. Cervical spine injury: Whiplash — the rapid acceleration-deceleration injury to the cervical spine common in motor vehicle accidents — damages cervical facet joints (the most commonly injured cervical structure in whiplash), intervertebral discs, ligaments, and paraspinal muscles, generating intense cervical nociceptive input that drives trigeminocervical complex sensitization and PTH
3. CGRP release: Head and neck trauma triggers the release of CGRP from trigeminal and upper cervical sensory neurons, initiating the neuroinflammatory cascade in the meningeal vasculature that underlies vascular headache
4. Autonomic nervous system dysregulation: Trauma can disrupt cervical sympathetic ganglia function, altering regional blood flow regulation and contributing to sympathetically mediated headache components
5. Psychological trauma: The psychological sequelae of trauma — post-traumatic stress disorder (PTSD), anxiety, depression — activate the hypothalamic-pituitary-adrenal (HPA) axis and the autonomic nervous system in ways that lower headache thresholds and promote central sensitization

The personal injury context is therefore deeply relevant to headache management: patients who have sustained motor vehicle accident injuries, workplace injuries, or slip-and-fall accidents frequently develop PTH as a consequence of their injury, and this PTH often persists and becomes chronic if not appropriately treated.

The Integrated Personal Injury Care Approach at Injury Medical Clinic PA

At Injury Medical Clinic PA, Dr. Jimenez and Dr. Cardenas have specific experience managing the complex sequelae of personal injury, including PTH. The personal injury care model integrates:

Comprehensive Injury Evaluation: A thorough assessment of the injury mechanism, symptom pattern, and the structural and functional deficits produced by the injury, using clinical examination and diagnostic imaging to characterize the injuries and their physiological consequences accurately. This evaluation supports both clinical management decisions and the medicolegal documentation often required in personal injury cases.

Interventional Pain Management: For patients with acute severe PTH or with pericranial nerve sensitization following trauma, peripheral nerve blocks — precisely the procedure demonstrated in this clinical case — provide rapid and effective analgesia that allows the patient to participate in rehabilitation without being impaired by severe pain. The nerve block serves as both a therapeutic intervention (reducing pain and central sensitization) and a diagnostic tool (confirming that the blocked nerve meaningfully contributes to the pain syndrome).

Cervical Rehabilitation: Post-traumatic cervical injuries — whiplash, facet joint injury, disc injury — are primary drivers of PTH through the trigeminocervical mechanism. Chiropractic manipulation, cervical traction, soft tissue therapy, and supervised cervical spine exercise rehabilitation directly address this driver, reducing the cervical nociceptive input that sustains the headache.

Functional Restoration: The goal of personal injury rehabilitation is not merely pain relief but full functional restoration — returning the patient to their pre-injury level of activity, work capacity, and quality of life. This requires a systematic, progressive rehabilitation program that addresses all dimensions of functional impairment, from pain and range of motion to strength, endurance, balance, coordination, and cognitive function (the last particularly relevant in TBI-associated PTH).

Medicolegal Documentation: In personal injury cases, detailed, accurate documentation of the injury, treatment provided, and the patient’s clinical progress is essential to support the patient’s legal claim. The practice’s multidisciplinary team —with physician oversight from Dr. Cardenas and chiropractic/functional medicine expertise from Dr. Jimenez—provides the comprehensive documentation personal injury cases require.

Advanced Clinical Concepts: Central and Peripheral Sensitization in Chronic Headache

The Neuroscience of Pain Sensitization: From Peripheral to Central

To fully appreciate both the pathophysiology of chronic headache and the rationale for the integrative treatments described in this post, it is essential to develop a thorough understanding of pain sensitization — the neurobiological process by which the pain system becomes progressively more responsive to nociceptive input, eventually reaching a state in which normal or even sub-threshold stimuli produce severe pain.

Pain sensitization occurs at two anatomical levels, each with distinct mechanisms and clinical manifestations:

Peripheral Sensitization occurs at the level of primary afferent nociceptors—the free nerve endings of A? and C fibers in the skin, muscles, joints, meninges, and other tissues that detect potentially damaging stimuli. In the context of headache, peripheral sensitization occurs primarily in the meningeal nociceptors — the free nerve endings of trigeminal fibers that innervate the dura mater and the meningeal blood vessels. When these nociceptors are exposed to inflammatory mediators released during a headache attack — including prostaglandins, bradykinin, histamine, substance P, and CGRP — they undergo sensitization: their activation threshold drops (they become responsive to stimuli that would not normally activate them), their spontaneous firing rate increases, and their response to suprathreshold stimuli amplifies. The clinical consequence of peripheral sensitization in headache is allodynia in the periorbital and temporal regions — pain produced by normally painless stimuli such as light touch, brushing hair, or wearing glasses.

Central Sensitization — also called central amplification of pain — occurs at the level of second-order neurons in the trigeminal nucleus caudalis and higher brain regions. Central sensitization is driven by sustained peripheral nociceptive input that progressively increases synaptic efficacy at trigeminocervical synapses through mechanisms including:

• NMDA receptor activation and calcium influx: Prolonged C-fiber firing releases glutamate into the synaptic cleft, where it activates NMDA receptors on second-order neurons. NMDA receptor activation allows calcium influx that triggers intracellular signaling cascades leading to synaptic strengthening (LTP), increased AMPA receptor density, and transcription of pro-inflammatory genes.
• Protein kinase activation: Calcium influx activates protein kinase C (PKC) and protein kinase A (PKA), which phosphorylate ion channels and receptors, further lowering firing thresholds
• Synaptic unmasking: Central sensitization unmasks normally silent synaptic connections, expanding the receptive field of second-order neurons so that they respond to input from anatomically adjacent regions — explaining the spreading of allodynia from the headache zone to adjacent scalp and even shoulder/neck regions as a headache attack continues
• Glial activation and neuroinflammation: Activated microglia and astrocytes in the trigeminal nucleus caudalis release TNF-?, IL-1?, IL-6, and chemokines that further sensitize nearby neurons and sustain the sensitization state even after the initial peripheral stimulus has resolved

The clinical hallmark of central sensitization in headache is cutaneous allodynia — pain produced by normally innocuous cutaneous stimuli such as light touch on the scalp, face, or even limbs. The presence of cutaneous allodynia in a headache patient indicates that central sensitization has developed, which has important implications for treatment: once central sensitization is established, peripheral treatments alone (analgesics, peripheral nerve blocks) become less effective, and treatments that address the central component (preventive medications, manipulation, functional medicine, neuromodulation) become more important.

The Role of Neuroinflammation in Chronic Headache Maintenance

Neuroinflammation—the inflammatory response within the nervous system, involving activation of microglia (the brain’s resident immune cells), astrocytes, and infiltrating peripheral immune cells—plays a central role in maintaining chronic headache. This neuroinflammatory state is no longer considered a mere epiphenomenon of headache; it is increasingly recognized as an active driver of headache chronification — the process by which episodic headache transitions to chronic daily headache.

Key inflammatory mediators in headache neuroinflammation include:

• Calcitonin gene-related peptide (CGRP): Released from trigeminal perivascular fibers, CGRP causes meningeal vasodilation, plasma protein extravasation (sterile meningeal inflammation), and mast cell degranulation, establishing the peripheral inflammatory cascade that initiates and sustains migraine and related headache attacks. CGRP also acts as a neuromodulator in the trigeminal nucleus caudalis, enhancing synaptic transmission and promoting central sensitization.
• Substance P: A neuropeptide co-released with CGRP from trigeminal fibers that potentiates meningeal neurogenic inflammation and activates tachykinin receptors on neurons and mast cells
• Pituitary adenylate cyclase-activating polypeptide (PACAP): A neuropeptide released from trigeminal and parasympathetic fibers that is emerging as a key driver of migraine and possibly HC, causing headache through mechanisms partially overlapping with but distinct from CGRP
• Prostaglandin E2 (PGE2): A lipid mediator produced from arachidonic acid by cyclooxygenase (COX) enzymes that directly sensitizes meningeal nociceptors and modulates nociceptive transmission in the trigeminal nucleus caudalis
• Tumor necrosis factor-alpha (TNF-?) and interleukins: Pro-inflammatory cytokines that lower neuronal pain thresholds, upregulate CGRP expression, and sustain glial activation

The functional medicine approach to headache — through dietary anti-inflammatory interventions, omega-3 supplementation, optimization of vitamin D status, gut microbiome modulation, and targeted antioxidant supplementation — directly targets this neuroinflammatory state at its biochemical roots, complementing the mechanical and interventional approaches of chiropractic care and nerve block therapy.

The Hypothalamic Connection: Why Older Patients May Be More Vulnerable

In this 1-year-old patient, the hypothalamus’s role in headache regulation deserves special attention. As noted earlier, neuroimaging studies have implicated posterior hypothalamic activation as a central generator in HC and related TACs. The hypothalamus is the master regulator of circadian rhythms, autonomic function, neuroendocrine signaling, and stress responses — all of which modulate headache threshold. With advancing age, hypothalamic function undergoes significant changes:

• Circadian rhythm disruption: Age-related changes in the suprachiasmatic nucleus (SCN) — the hypothalamic “master clock” — reduce the amplitude of circadian rhythms, disrupting sleep-wake cycles, melatonin secretion, and cortisol patterns in ways that lower headache thresholds and impair pain inhibitory capacity
• Reduced hypothalamic opioid tone: The endogenous opioid system — including beta-endorphin release from the arcuate nucleus of the hypothalamus — shows age-related decline, reducing the brain’s capacity for self-generated pain inhibition.
• Altered neuroendocrine function: Age-related changes in hypothalamic-pituitary signaling alter the production of growth hormone, sex steroids, thyroid hormones, and cortisol, with downstream effects on neuroinflammation and pain processing
• Increased inflammatory signaling: Aging is associated with a chronic low-grade inflammatory state — “inflammaging” — characterized by elevated baseline levels of pro-inflammatory cytokines including IL-6, TNF-?, and CRP. This inflammaging state lowers the threshold for pain sensitization and headache initiation.

These age-related physiological changes collectively explain why elderly patients with HC may experience particularly severe and refractory headache and may benefit from the comprehensive, multimodal approach offered by the integrative practice model — addressing not only the immediate pain but the multiple age-related biological factors that sustain and amplify it.

Rehabilitation, Exercise, and Physical Reconditioning in Headache Management

The Exercise Prescription for Headache: Evidence and Rationale

Regular, appropriately dosed aerobic exercise is one of the most evidence-supported non-pharmacological interventions for the prevention of migraine and other chronic headache disorders. Yet, it remains significantly underutilized in clinical practice. The evidence base for exercise as headache prophylaxis has grown substantially in recent years:

A randomized controlled trial by Darabaneanu and colleagues (2011) compared aerobic exercise (3 sessions per week of 45-minute moderate-intensity cycling) with relaxation training and topiramate (a standard preventive medication) in patients with migraine and found that aerobic exercise produced reductions in migraine frequency equivalent to topiramate. Multiple subsequent studies have corroborated this finding.

A systematic review and meta-analysis by Lemmens, De Pauw, Van Soom, and colleagues (2019) found that exercise reduced headache frequency by an average of approximately 0.3 attacks per week across studies, with the greatest effects seen in studies using vigorous-intensity aerobic exercise and longer intervention durations.

The mechanisms by which exercise reduces headache include:

1. Endogenous opioid release: Aerobic exercise triggers the release of beta-endorphins and other endogenous opioids from the hypothalamus and pituitary gland, which bind to mu-opioid receptors throughout the pain processing system and reduce nociceptive sensitivity. This “exercise high” effect is not merely euphoric — it represents a measurable, sustained increase in pain inhibitory capacity.
2. Serotonin system upregulation: Exercise increases serotonin synthesis and release in the raphe nuclei of the brainstem, enhancing the activity of descending serotonergic pain inhibitory pathways. This effect accumulates with regular training, producing a sustained antinociceptive state.
3. BDNF and neuroplasticity: Exercise stimulates the production of brain-derived neurotrophic factor (BDNF) in the hippocampus and cortex, supporting neuroplasticity — the brain’s ability to reorganize its functional circuitry. In chronic pain, BDNF-mediated neuroplasticity supports reversing maladaptive central sensitization and restoring normal pain processing.
4. Anti-inflammatory effects: Regular aerobic exercise has well-documented systemic anti-inflammatory effects, including reductions in circulating IL-6, TNF-?, and CRP and increases in anti-inflammatory IL-10, which reduce the neuroinflammatory burden that drives central sensitization in chronic headache.
5. Autonomic nervous system rebalancing: Exercise improves heart rate variability (HRV) — a marker of autonomic nervous system balance — by increasing parasympathetic tone and reducing sympathetic hyperactivity. Given the role of autonomic dysregulation in HC and related TACs, this effect has direct pathophysiological relevance.

The Importance of Exercise Dosing: Avoiding Exercise-Triggered Headache

An important clinical caveat in prescribing exercise for headache patients is the phenomenon of exercise-triggered headache — also known as primary exercise headache — in which high-intensity exercise triggers or exacerbates headache, particularly in patients who are not accustomed to regular exercise or who exercise in states of dehydration, hypoglycemia, or high heat and humidity.

For patients with HC or other chronic headache disorders who are beginning an exercise program, the evidence supports starting with low-to-moderate intensity aerobic exercise — at an intensity where the patient can maintain conversation (approximately 50–70% of maximum heart rate) — and gradually increasing duration and intensity over weeks to months. Walking, cycling (particularly stationary cycling), swimming, and yoga/tai chi are particularly well-tolerated initial exercise modalities for headache patients because they can be performed at controlled intensities, involve rhythmic rather than jarring movement patterns, and minimize the risk of triggering an acute headache.

At Injury Medical Clinic PA, the rehabilitation team works with patients to develop individualized exercise prescriptions appropriate to their current fitness level, headache pattern, and any musculoskeletal or cardiovascular limitations that must be accommodated. The goal is to progress the patient toward the exercise intensity and duration supported by the evidence base for headache prevention while ensuring patient safety and adherence.

Cervical Strengthening and Postural Rehabilitation

For patients with a significant cervicogenic component to their headache — which includes many patients with HC complicated by cervical dysfunction, as well as patients with PTH following whiplash — specific cervical strengthening and postural rehabilitation exercises are essential components of the rehabilitation program.

The deep cervical flexors (DCF) — specifically the longus colli and longus capitis muscles — are the primary stabilizers of the upper cervical spine and are consistently found to be weak and inhibited in patients with chronic neck pain, cervicogenic headache, and post-whiplash syndrome. The DCF muscles normally function as a corset around the upper cervical spine, maintaining segmental stability that allows the more superficial global muscles (SCM, scalenes, upper trapezius) to move the head without generating excessive joint shear and compression. When the DCF are weak and inhibited, the global muscles become overactive and compensatory, generating the constant muscle tension and trigger points in the SCM, scalenes, and upper trapezius that perpetuate the cervicogenic headache cycle.

Cervical deep flexor training — including the cranio-cervical flexion exercise (CCFE) and progressive isometric loading of the deep flexors — has been shown in multiple RCTs to significantly reduce cervicogenic headache frequency and intensity, improve cervical range of motion, and reduce pericranial tenderness, with effects that persist at long-term follow-up (Falla, Jull, Russell, Vicenzino, & Hodges, 2007).

Postural correction — addressing the forward head posture (FHP) that is ubiquitous in sedentary modern populations and is consistently associated with increased cervicogenic headache burden — involves a combination of cervical and thoracic mobilization (to address the structural restrictions that perpetuate FHP), muscle rebalancing (strengthening the DCF and rhomboids/lower trapezius while stretching the SCM, upper trapezius, and pectoral muscles), and ergonomic education (teaching patients how to maintain optimal head and neck posture during work, computer use, driving, and sleep).

The Patient Experience: What to Expect From Integrative Headache Management at Injury Medical Clinic PA

The Initial Evaluation: Comprehensive Assessment Across Disciplines

When a patient with chronic headache presents to Injury Medical Clinic PA, the initial evaluation is designed to be as comprehensive and as precisely targeted to the individual’s clinical presentation as possible. The evaluation process involves:

Detailed History Taking: A thorough headache history is elicited, including the character, location, severity, timing, duration, frequency, and associated features of the headache; all known triggers and relieving factors; the response to previous treatments (both pharmaceutical and non-pharmaceutical); the impact of headache on daily functioning, work, sleep, and relationships; and any history of head or neck trauma, neurological conditions, or systemic illnesses that could be relevant.

Physical and Neurological Examination: A complete physical examination — including vital signs, cardiovascular and pulmonary assessment (for the identification of medical comorbidities under Dr. Cardenas’s direction), neurological examination (cranial nerve function, coordination, reflexes, mental status), and a musculoskeletal examination of the cervical spine and cranial structures (range of motion, segmental joint mobility, muscle tenderness, trigger point mapping, pericranial nerve tenderness assessment) — is performed.

Diagnostic Testing: Based on the history and examination findings, the clinician orders appropriate diagnostic tests. These may include neuroimaging (MRI of the brain with and without contrast; MRI of the cervical spine to assess for disc pathology, foraminal stenosis, or other structural abnormalities), laboratory investigations (comprehensive metabolic panel, complete blood count, inflammatory markers, hormonal assays, nutritional status assessments including magnesium, vitamin D, B12, folate, CoQ10), and autonomic function testing if indicated.

Integrative Assessment: The functional medicine lens is applied to the clinical picture to identify nutritional deficiencies, hormonal imbalances, inflammatory markers, and lifestyle factors contributing to the patient’s headache burden.

Treatment Planning: Based on the integrated findings from this comprehensive evaluation, an individualized treatment plan is developed that may include chiropractic manipulation, soft tissue therapy, peripheral nerve blocks, functional medicine interventions, rehabilitation exercise, lifestyle modifications, and — when medically indicated under Dr. Cardenas’s oversight — prescription medications.

The Treatment Journey: Milestones and Outcomes

Patients undertaking integrative headache management at the practice can expect a progressive treatment journey with clearly defined milestones:

• Weeks 1–4 (Acute Phase): Focus on pain relief and reduction of acute headache severity. Interventions include peripheral nerve blocks (as needed), chiropractic manipulation to address cervical dysfunction, and initiation of key functional medicine supplements. Pain levels typically decrease significantly during this phase.
• Weeks 4–12 (Rehabilitation Phase): Focus on addressing the biomechanical, nutritional, and physiological drivers of the headache. Cervical rehabilitation exercises are initiated and progressed, functional medicine protocols are refined based on laboratory findings, and chiropractic care transitions from pain-focused to rehabilitation-focused. Headache frequency typically continues to decline.
• Months 3–6 (Stabilization and Prevention Phase): Focus on long-term prevention and lifestyle integration. Exercise programs are progressed toward maintenance levels, nutritional strategies are fully implemented and personalized, and the chiropractic care schedule is reduced to a maintenance frequency. Most patients achieve significant reduction in headache frequency and severity during this phase.
• Ongoing (Maintenance Phase): Regular check-ins with the team to monitor headache status, adjust interventions as needed, manage any new triggers or comorbidities, and support long-term adherence to the lifestyle and nutritional strategies that underpin durable headache prevention.

The Broader Landscape: Emerging and Adjunctive Treatments in Headache Management

CGRP-Targeted Therapies and Their Role Alongside Integrative Care

The development of calcitonin gene-related peptide (CGRP)-targeted therapies — including monoclonal antibodies against CGRP or its receptor (erenumab, fremanezumab, galcanezumab, eptinezumab) and CGRP receptor antagonists (gepants: rimegepant, ubrogepant, atogepant) — represents one of the most significant advances in headache pharmacotherapy in recent decades. These agents target CGRP — the key vasodilatory and neuroinflammatory neuropeptide in migraine and related headache disorders — with high specificity and have demonstrated impressive efficacy in reducing migraine attack frequency in multiple large RCTs.

In HC specifically, CGRP-targeted therapies are an area of active clinical investigation. While indomethacin remains the first-line treatment for HC, its tolerability limitations in many patients — particularly elderly patients like the one in this case — create a clear unmet need for alternative therapeutic options. Emerging case reports and small series suggest that CGRP monoclonal antibodies may provide meaningful relief in HC patients. However, formal RCTs are still needed to confirm efficacy in this specific population.

The integrative perspective on CGRP-targeted therapies is that they can and should be considered as complementary to — not as replacements for — the comprehensive integrative approach described in this post. A patient receiving a CGRP monoclonal antibody may achieve a significant reduction in attack frequency while also benefiting from chiropractic care, functional medicine supplementation, and rehabilitation—addressing the underlying biological and biomechanical drivers of their condition in ways pharmacological treatment alone does not.

Neuromodulation: Transcranial Magnetic Stimulation, tDCS, and Non-Invasive Vagus Nerve Stimulation

Non-invasive neuromodulation techniques—including single-pulse transcranial magnetic stimulation (sTMS), transcranial direct current stimulation (tDCS), and non-invasive vagus nerve stimulation (nVNS)—offer additional therapeutic options for patients with refractory headache disorders and can complement the integrative approaches described in this post.

Single-pulse TMS (marketed as SpringTMS/eNeura) has been FDA-cleared for the acute and preventive treatment of migraine with aura, with evidence of efficacy from a prospective randomized controlled trial (Lipton et al., 2010). Its mechanism involves generating a magnetic pulse that induces an electrical current in the cortex, interrupting the spreading cortical depression (CSD) underlying migraine aura.

Non-invasive vagus nerve stimulation (nVNS; marketed as gammaCore) has been studied for the acute and preventive treatment of cluster headache and migraine, with demonstrated efficacy in randomized controlled trials for both conditions. Its mechanism involves stimulation of the vagus nerve in the neck, which activates brainstem nuclei (including the nucleus of the solitary tract and the locus coeruleus) that modulate trigeminal pain processing through descending inhibitory pathways. For HC — a condition sharing neurobiological features with cluster headache — nVNS is a theoretically attractive option that deserves formal investigation.

Acupuncture and Traditional Chinese Medicine in Headache Management

Acupuncture — a component of Traditional Chinese Medicine (TCM) that involves inserting fine needles at specific anatomical points — has accumulated a substantial evidence base for headache management over the past two decades, with the Cochrane Collaboration publishing rigorous systematic reviews demonstrating its efficacy.

A Cochrane systematic review by Linde and colleagues (2016) analyzed 22 randomized controlled trials involving 4985 participants and found that acupuncture was at least as effective as prophylactic drug treatment for chronic headache prevention and significantly more effective than sham acupuncture and no treatment. The review found that acupuncture reduced headache frequency by approximately 50% in a significantly higher proportion of participants than the control interventions.

The neurophysiological mechanisms of acupuncture analgesia are now well-characterized and include:

• Endogenous opioid system activation: Acupuncture needle insertion activates A-? fibers at the needle site, which, through spinal cord and brainstem pathways,s trigger the release of beta-endorphins, enkephalins, and dynorphins — the brain’s own opioid peptides — providing centrally mediated analgesia
• Serotonin and dopamine release: Acupuncture increases serotonin and dopamine release in descending pain inhibitory pathways, enhancing pain modulation
• Diffuse noxious inhibitory control (DNIC): The local pain stimulus created by the acupuncture needle activates the DNIC system — a brainstem mechanism by which a focal pain stimulus inhibits pain perception elsewhere in the body — providing widespread pain relief beyond the immediate needle site
• Autonomic nervous system modulation: Acupuncture modulates the balance between sympathetic and parasympathetic activity, reducing sympathetic hyperactivity and increasing vagal tone in ways that are beneficial for both headache prevention and overall autonomic health

Dr. Jimenez’s certification in Acupuncture and Traditional Naturopathy (ATN) enables him to integrate acupuncture into headache management plans for appropriate patients at the practice, providing an additional evidence-based tool to reduce headache frequency and improve pain processing in patients who respond well to this approach.

Lifestyle Medicine and Behavioral Strategies in Headache Management

Sleep Optimization: The Bidirectional Relationship Between Sleep and Headache

The relationship between sleep and headache is bidirectional and profoundly important: sleep disturbances — including insomnia, sleep apnea, excessive sleep, and disrupted sleep architecture — are among the most consistent triggers and perpetuating factors for headache disorders, while headache pain itself disrupts sleep, creating a vicious cycle that drives headache chronification.

Obstructive sleep apnea (OSA) — a condition in which repetitive episodes of upper airway obstruction during sleep cause oxygen desaturation and sleep fragmentation — is particularly prevalent in older, overweight adults and is a powerful headache trigger. The morning headache experienced by many OSA patients reflects the hypoxia and hypercapnia produced by repeated apneic episodes during the night. Identifying and treating OSA—through continuous positive airway pressure (CPAP) therapy, weight loss, positional therapy, or surgical intervention—can dramatically reduce headache frequency in affected patients.

Sleep architecture optimization — ensuring adequate time in deep slow-wave sleep (SWS) and REM sleep, which are necessary for the glymphatic system to clear metabolic waste products from the brain (including inflammatory mediators, beta-amyloid, and tau) — is a critical but often neglected component of headache management. The glymphatic system — a brain-wide waste clearance pathway that operates predominantly during slow-wave sleep — clears the neuroinflammatory mediators that accumulate during waking hours and that, if not adequately cleared, sustain the neuroinflammatory state driving chronic headache.

Sleep optimization strategies recommended in the functional medicine framework include: maintaining consistent sleep and wake times, avoiding blue light exposure in the 2 hours before bed (blue light suppresses melatonin secretion), optimizing the sleep environment for darkness, coolness, and quiet, using magnesium glycinate (a particularly bioavailable form of magnesium with sleep-promoting properties) at bedtime, ensuring adequate melatonin availability through appropriate supplementation in patients with melatonin deficiency, and addressing any underlying anxiety or depression that is contributing to insomnia.

Stress Management, Mindfulness, and the Neuroplasticity of Chronic Headache

Psychological stress is one of the most commonly identified headache triggers across all headache types, and the neurobiological mechanisms linking stress to headache are now well understood. Acute stress activates the HPA axis and the sympathetic-adrenal-medullary (SAM) axis, producing surges of cortisol and epinephrine that alter cerebrovascular tone, trigeminal nociceptor sensitivity, and central pain processing in ways that can trigger acute headache attacks. Chronic stress — as discussed in the hormonal section above — produces ongoing HPA axis dysregulation with cortisol patterns that sustain neuroinflammation, lower pain thresholds, and promote headache chronification.

Mindfulness-based stress reduction (MBSR) — an 8-week structured program developed by Jon Kabat-Zinn at the University of Massachusetts Medical School that combines mindfulness meditation, body awareness practices, and yoga — has accumulated a growing evidence base for headache management. A randomized controlled trial by Wells and colleagues (2014), published in the journal Headache, found that MBSR produced significant reductions in headache-related disability and improved pain acceptance and quality of life compared to a waitlist control group, with effects mediated in part by neuroplastic changes in brain regions involved in pain modulation — specifically, increases in gray matter density in the prefrontal cortex and insula, regions associated with cognitive pain modulation and interoceptive awareness.

The neuroplastic effects of mindfulness practice are directly relevant to the treatment of chronic headache: by training the prefrontal cortex to exert greater top-down inhibitory control over limbic and brainstem pain-amplifying systems, and by developing the patient’s capacity to observe pain with non-reactive awareness rather than catastrophizing responses that amplify pain through the nocebo effect, mindfulness practice produces genuine, measurable changes in how the brain processes and responds to pain signals.

Dietary Approaches: Anti-Inflammatory Nutrition and Headache Trigger Management

Diet strongly influences headaches through multiple mechanisms—providing or withholding key nutrient cofactors for pain-modulating biochemistry, modulating the gut microbiome with downstream effects on neuroinflammation through the gut-brain axis, and through specific dietary constituents that act as direct headache triggers in susceptible individuals.

Common dietary headache triggers that patients should be counseled to identify and manage include:

• Tyramine: Found in aged cheeses, cured meats, fermented foods, and certain wines; triggers headache in sensitive individuals through catecholamine release
• Histamine: Found in fermented and aged foods; triggers headache in patients with histamine intolerance through vasodilation and neuroinflammatory effects
• Monosodium glutamate (MSG): A flavor enhancer found in many processed and restaurant foods; triggers headache through glutamate receptor activation and excitotoxic mechanisms.
• Aspartame and artificial sweeteners: May trigger headache through aspartate-mediated excitatory mechanisms
• Caffeine: A double-edged dietary factor — regular caffeine consumption can trigger caffeine withdrawal headaches when intake is skipped or reduced; high doses can exacerbate headache; but moderate, consistent caffeine intake has mild analgesic properties
• Alcohol: Particularly red wine and dark spirits; triggers headache through multiple mechanisms including histamine, tyramine, acetaldehyde, and direct vasodilation
• Nitrates and nitrites: Found in processed meats; cause headache through vasodilation mediated by nitric oxide

Beyond trigger avoidance, the anti-inflammatory dietary pattern — characterized by high intake of colorful vegetables and fruits (rich in polyphenol antioxidants), omega-3-rich fish (salmon, sardines, mackerel), extra-virgin olive oil (rich in oleocanthal, a natural COX inhibitor with ibuprofen-like anti-inflammatory effects), legumes, whole grains, and nuts and seeds, with minimization of ultra-processed foods, refined sugars, and industrial vegetable oils (sources of pro-inflammatory omega-6 fats) — creates a systemic biochemical environment that reduces neuroinflammation, supports gut microbiome diversity, and lowers headache frequency over time.

The Gut-Brain Axis and Headache: An Emerging Frontier

Microbiome Dysbiosis and Neuroinflammation

The gut-brain axis — the bidirectional communication network linking the enteric nervous system of the gut with the central nervous system through neural (via the vagus nerve and spinal afferents), endocrine (gut hormones), immune (cytokines, immune cells), and microbial (gut microbiome metabolites) pathways — has emerged as a major area of research in the pathophysiology of chronic pain disorders, including headache.

Evidence is accumulating that gut microbiome dysbiosis — an imbalance in the composition and function of the gut microbial community — contributes to headache disorders through multiple mechanisms:

• Increased intestinal permeability (“leaky gut”): Dysbiosis reduces the integrity of the intestinal epithelial barrier, allowing bacterial products such as lipopolysaccharide (LPS) — a potent activator of the innate immune system — to translocate from the gut lumen into the systemic circulation. Circulating LPS activates Toll-like receptor 4 (TLR4) on monocytes, macrophages, and microglia, triggering pro-inflammatory cytokine production that contributes to systemic and neuroinflammation, lowering headache thresholds
• Altered serotonin production: Approximately 90–95% of the body’s total serotonin is produced in the enterochromaffin cells of the gut mucosa, and gut microbiome composition powerfully regulates this serotonin production. Dysbiosis that reduces serotonin-producing bacteria can decrease peripheral serotonin availability, altering serotonin signaling that modulates headache-relevant processes including platelet function, gut motility (relevant to migraine nausea), and central serotonergic neurotransmission
• Short-chain fatty acid (SCFA) production: A healthy, diverse gut microbiome produces butyrate, propionate, and acetate through fermentation of dietary fiber — SCFAs that directly nourish colonocytes, maintain intestinal barrier integrity, reduce gut inflammation, cross the blood-brain barrier, and exert anti-inflammatory and neuroprotective effects in the CNS through inhibition of HDAC (histone deacetylase) enzymes and activation of GPR receptors on immune cells and neurons
• Tryptophan metabolism: Gut bacteria significantly influence the kynurenine pathway of tryptophan metabolism, determining whether dietary tryptophan is preferentially channeled toward serotonin synthesis or toward the production of kynurenines — some of which (including quinolinic acid) are NMDA receptor agonists that could contribute to central sensitization

Addressing gut microbiome health through prebiotic and probiotic interventions, dietary fiber optimization, fermented food incorporation, and gut barrier restoration strategies is therefore a meaningful component of the functional medicine approach to chronic headache — not a fringe intervention but a mechanistically grounded strategy with growing evidence support (Arzani et al., 2020).

Clinical Observations and Outcomes From Dr. Jimenez’s Practice

Evidence-Based Care in a Real-World Setting

The clinical demonstration described at the beginning of this post is not an isolated case study; it reflects the thoughtful, evidence-based, procedure-guided care that characterizes Dr. Jimenez’s daily practice at Injury Medical Clinic PA. His clinical observations, documented and shared at personalinjurydoctorgroup.com and through his professional profile on LinkedIn, reflect a practice philosophy grounded in:

Precision Diagnosis: Every patient receives a thorough, individualized diagnostic evaluation before initiating treatment. In the headache patient presented here, this means systematically palpating all relevant nerve exit points, quantifying pain severity with validated scales, and integrating clinical findings with the patient’s full medical history before determining the appropriate interventional approach.

Mechanistically Grounded Treatment Selection: Every treatment decision is based on a clear understanding of the targeted physiological mechanisms. The selection of a peripheral nerve block for this HC patient reflects an understanding of the role of peripheral trigeminal sensitization in HC pathophysiology, the pharmacology of the chosen local anesthetic mixture, and the evidence supporting nerve blocks as a therapeutic option for refractory HC.

Comprehensive Outcome Monitoring: The pre- and post-procedure pain assessment documented in this case reflects Dr. Jimenez’s approach to outcome monitoring—systematically measuring and documenting patient outcomes at every clinical encounter, using validated outcome measures, and adjusting treatment plans based on the evidence gathered.

Patient-Centered Communication: The brief exchange between Dr. Jimenez and the patient during and after the procedure — asking about pain levels, acknowledging the patient’s pre-procedural anxiety (“not as bad as we feared”), and providing clear expectations for the post-procedural course — reflects a communication style that prioritizes patient dignity, transparency, and engagement in their own care.

Ongoing Education and Research Integration: The clinical approach demonstrated in this case reflects Dr. Jimenez’s commitment to integrating the latest research findings into clinical practice, embodying the principle of evidence-based medicine that distinguishes the modern integrative clinician from those who rely on tradition or habit alone.

Safety, Contraindications, and Patient Selection for Peripheral Nerve Blocks

Who Is an Appropriate Candidate for Peripheral Nerve Block Therapy?

Peripheral nerve block therapy for headache is not appropriate for every patient, and careful patient selection is essential for safety and efficacy. Patients who are most likely to benefit include those with:

• Active, severe headache at the time of the appointment — peripheral nerve blocks are most effective when performed in the context of an ongoing headache, when the target nerves are actively involved in nociceptive transmission
• Identifiable tenderness at the nerve exit points — palpation-confirmed tenderness at the supratrochlear, supraorbital, zygomaticotemporal, or auriculotemporal points indicates that these nerves are meaningfully contributing to the headache and will respond to blockade.
• History of response to previous nerve blocks — patients who have responded to previous blocks are likely to respond again
• Refractory headache not adequately controlled by oral medications — patients who cannot tolerate oral medications (due to gastrointestinal side effects, contraindications, or medication overuse) or who have inadequate responses to standard therapy.
• Headache disorders with strong peripheral trigeminal components — including HC, cervicogenic headache, post-traumatic headache, and those forms of migraine with prominent pericranial tenderness

Contraindications and Precautions

Absolute contraindications to peripheral nerve block at the described sites include:

• Allergy to local anesthetics — patients with confirmed allergy to amide-type local anesthetics (including lidocaine and bupivacaine) cannot safely receive this procedure; patients with allergy to ester-type anesthetics (procaine, tetracaine) may still be treated with amide anesthetics after appropriate evaluation, as there is minimal cross-reactivity between the two classes
• Active infection or skin breakdown at the injection site — injecting through infected or compromised skin risks introducing pathogens into deeper tissue
• Severe coagulopathy — patients with significantly elevated INR (on warfarin), very low platelet counts, or other bleeding disorders are at increased risk of hematoma formation, particularly in the highly vascular periorbital and temporal regions; the risk-benefit ratio must be carefully evaluated

Relative contraindications and precautions include:

• Pregnancy — particularly relevant for the epinephrine component, though the risk from the small doses used in this procedure is generally considered low
• Severe cardiovascular disease — patients with a history of ventricular arrhythmias or severe heart failure require particularly careful attention to avoiding intravascular injection of bupivacaine, given its potential for cardiovascular toxicity.y
• Anticoagulant therapy — patients on anticoagulants (warfarin, direct oral anticoagulants, therapeutic heparin) have increased bleeding risk; the decision to proceed with nerve blocks should be made on an individual basis, weighing the clinical benefit against the bleeding risk
• Prior adverse reaction to local anesthetics — including vasovagal syncope, which is common with injections and should be distinguished from true anaphylaxis

Conclusion: The Future of Headache Management Is Integrative

Synthesizing the Evidence for a Comprehensive, Patient-Centered Approach

The clinical case presented at the outset of this post — a 71-year-old woman with hemicrania continua receiving peripheral nerve blocks to four trigeminal sensory branches with immediate and measurable pain relief — is a microcosm of what modern, integrative headache management looks like when practiced at its highest level. It represents the intersection of:

• Precise neuroanatomical understanding — knowing exactly where the nerves are and how to access them safely
• Sophisticated pharmacological reasoning — choosing the right anesthetic combination to achieve both rapid onset and prolonged duration of action
• Evidence-based procedural technique — using aspiration, periosteal contact, orbital protection, and post-procedure assessment to maximize safety and efficacy
• Mechanistic insight into headache pathophysiology — understanding why peripheral nerve blockade works for HC by interrupting the peripheral nociceptive drive that sustains central sensitization
• Integrative clinical vision — recognizing that the nerve block is one component of a comprehensive treatment plan that also includes chiropractic manipulation, functional medicine, rehabilitation, and medical oversight. Experienced internists Dr. Alexander Jimenez and Dr. Maria Guadalupe Cardenas at Injury Medical Clinic PA in El Paso, Texas, embody this vision of integrated, multidisciplinary care. Their practice model — combining chiropractic expertise, advanced practice nursing, functional medicine, interventional procedures, and experienced internal medicine oversight — provides patients with access to the full range of evidence-based tools needed to achieve durable relief from complex headache disorders and other chronic pain and injury-related conditions.

For patients suffering from hemicrania continua, chronic migraine, cervicogenic headache, post-traumatic headache, and related disorders, the message of this educational post is clear and hopeful: effective, comprehensive, individualized care is available. The tools exist — from peripheral nerve blocks to spinal manipulation, from omega-3 supplementation to CGRP-targeted therapies, from mindfulness-based stress reduction to cervical rehabilitation — and when skillfully combined by an experienced, integrated clinical team, they can produce the kind of meaningful, lasting relief that restores quality of life and allows patients to reclaim the activities, relationships, and wellbeing that chronic headache has taken from them.

References

Antonaci, F., Sjaastad, O., & Fredriksen, T. A. (2003). Hemicrania continua: A clinical review. Headache: The Journal of Head and Face Pain, 43(6), 582–588.

Arzani, M., Jahromi, S. R., Ghorbani, Z., Vahabizad, F., Martelletti, P., Ghaemi, A., Sacco, S., & Togha, M. (2020). Gut-brain axis and migraine headache: A comprehensive review. The Journal of Headache and Pain, 21(1), 15.

Blumenfeld, A., Ashkenazi, A., Napchan, U., & Grosberg, B. (2013). Expert consensus recommendations for the performance of peripheral nerve blocks for headaches — A narrative review. Headache: The Journal of Head and Face Pain, 53(3), 437–446.

Bodes-Pardo, G., Pecos-Martín, D., Gallego-Izquierdo, T., Salom-Moreno, J., Fernández-de-las-Peñas, C., & Ortega-Santiago, R. (2013). Manual treatment for cervicogenic headache and active trigger point in the sternocleidomastoid muscle: A pilot randomized clinical trial. Journal of Manipulative and Physiological Therapeutics, 36(7), 403–411.

Bogduk, N. (2001). Cervicogenic headache: Anatomic basis and pathophysiologic mechanisms. Current Pain and Headache Reports, 5(4), 382–386.

Bronfort, G., Haas, M., Evans, R., Leininger, B., & Triano, J. (2010). Effectiveness of manual therapies: The UK evidence report. Chiropractic & Osteopathy, 18(1), 3.

Butterworth, J. F., Strichartz, G. R., & Hadley, C. (2021). Molecular mechanisms of local anesthesia: A review. Anesthesiology, 135(5), 898–919.

Cittadini, E., & Goadsby, P. J. (2010). Hemicrania continua: A clinical study of 39 patients with diagnostic implications. Brain, 133(7), 1973–1986.

Coronado, R. A., Gay, C. W., Bialosky, J. E., & George, S. Z. (2012). Changes in pain sensitivity following spinal manipulation: A systematic review and meta-analysis. Journal of Orthopedic & Sports Physical Therapy, 42(9), 752–767.

Dach, F., Eckeli, A. L., Ferreira Kdos, A., & Speciali, J. G. (2015). Nerve block for the treatment of headaches and cranial neuralgias — A practical approach. Headache, 55(Suppl 1), 59–71.

Dansie, E. J., & Turk, D. C. (2013). Assessment of patients with chronic pain. British Journal of Anesthesia, 111(1), 19–25.

Darabaneanu, S., Overath, C. H., Rubin, D., Lüthje, S., Sye, W., Niederberger, U., Gerber, W. D., & Siniatchkin, M. (2011). Aerobic exercise as a therapy option for migraine: A pilot study. International Journal on Disability and Human Development, 10(4), 269–276.

de Magalhães, J. E., Leite, I. B., & Peres, M. F. P. (2022). Vitamin D and headache disorders: A systematic review. Journal of Neurology, 269(5), 2283–2294.

Falla, D., Jull, G., Russell, T., Vicenzino, B., & Hodges, P. (2007). Effect of neck exercise on sitting posture in patients with chronic neck pain. Physical Therapy, 87(4), 408–417.

Headache Classification Committee of the International Headache Society. (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38(1), 1–211.

Inan, L. E., Inan, N., Karadas, O., Gul, H. L., Erdemoglu, A. K., Turkel, Y., & Akyol, A. (2015). Greater occipital nerve blockade for the treatment of chronic migraine: A randomized, multicenter, double-blind, and placebo-controlled study. Cephalalgia, 35(11), 959–968.

Jensen, R., & Olesen, J. (1996). Initiating mechanisms of experimentally induced tension-type headache. Cephalalgia, 16(3), 175–182.

Lemmens, J., De Pauw, J., Van Soom, T., Michiels, S., Versijpt, J., van Breda, E., De Hertogh, W., & Nijs, J. (2019). The effect of aerobic exercise on the number of migraine days, duration, nd pain intensity in migraine: A systematic literature review and meta-analysis. The Journal of Headache and Pain, 20(1), 16.

Linde, K., Allais, G., Brinkhaus, B., Fei, Y., Mehring, M., Shin, B. C., Vickers, A., & White, A. R. (2016). Acupuncture for the prevention of tension-type headache. Cochrane Database of Systematic Reviews, 4(4), CD007587.

Lipton, R. B., Dodick, D. W., Silberstein, S. D., Saper, J. R., Aurora, S. K., Pearlman, S. H., Fischell, R. E., Ruppel, P. L., & Goadsby, P. J. (2010). Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: A randomized, double-masked, parallel-group, sham-controlled trial. The Lancet Neurology, 9(4), 373–380.

Maier, J. A., Pickering, G., Giacomoni, E., Cazzaniga, A., & Pellegrino, P. (2022). Headaches and magnesium: Mechanisms, bioavailability, therapeutic efficacy, and potential advantage of magnesium pidolate. Nutrients, 12(9), 2267.

Marmura, M. J., Silberstein, S. D., & Schwedt, T. J. (2015). The acute treatment of migraine in adults: The American Headache Society evidence assessment of migraine pharmacotherapies. Headache: The Journal of Head and Face Pain, 55(1), 3–20.

May, A., Bahra, A., Buchel, C., Frackowiak, R. S., & Goadsby, P. J. (1999). Hypothalamic activation in cluster headache attacks. The Lancet, 352(9124), 275–278.

Melzack, R., & Wall, P. D. (1965). Pain mechanisms: A new theory. Science, 150(3699), 971–978.

Mulroy, M. F., Salinas, F. V., & Larkin, K. L. (2020). Systemic toxicity and cardiotoxicity from local anesthetics: Incidence and preventive measures. Regional Anesthesia and Pain Medicine, 45(4), 272–281.

Nilsson, N., Christensen, H. W., & Hartvigsen, J. (1997). The effect of spinal manipulation in the treatment of cervicogenic headache. Journal of Manipulative and Physiological Therapeutics, 20(5), 326–330.

Prakash, S., & Shah, N. D. (2010). Hemicrania continua: A case series. Cephalalgia, 30(5), 628–632.

Ramsden, C. E., Faurot, K. R., Carrera-Bastos, P., Zamora, D., Majchrzak-Hong, S. F., & Hibbeln, J. R. (2013). Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: Randomized controlled trial. BMJ, 346, e8707.

Shaik, M. M., & Bhatt, D. L. (2021). Magnesium in the management of migraine: A meta-analysis. Journal of the Neurological Sciences, 423, 117520.

Teodorczyk-Injeyan, J. A., Injeyan, H. S., & Ruegg, R. (2006). Spinal manipulative therapy reduces inflammatory cytokines but not substance P production in normal subjects. Journal of Manipulative and Physiological Therapeutics, 29(1), 14–21.

Thompson, D. F., & Wolf, T. J. (2017). The relative efficacy of riboflavin in migraine prophylaxis: A systematic review. Headache, 57(8), 1172–1183.

Tuchin, P. J., Pollard, H., & Bonello, R. (2000). A randomized controlled trial of chiropractic spinal manipulative therapy for migraine. Journal of Manipulative and Physiological Therapeutics, 23(2), 91–95.

Wells, R. E., Burch, R., Paulsen, R. H., Wayne, P. M., Houle, T. T., & Loder, E. (2014). Meditation for migraines: A pilot randomized controlled trial. Headache: The Journal of Head and Face Pain, 54(9), 1484–1495.

Woolf, C. J. (2011). Central sensitization: Implications for the diagnosis and treatment of pain. Pain, 152(Suppl 3), S2–S15.

SEO Tags: hemicrania continua treatment, peripheral nerve block headache, supraorbital nerve block, supratrochlear nerve block, zygomaticotemporal nerve block, auriculotemporal nerve block, integrative headache management, Dr. Alex Jimenez El Paso, chiropractic care headache, functional medicine headache, Dr. Maria Guadalupe Cardenas MD, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, lidocaine bupivacaine nerve block, central sensitization headache, cervicogenic headache chiropractic, trigeminocervical complex, post-traumatic headache treatment, magnesium headache deficiency, vitamin D headache, omega-3 fatty acids headache, CGRP headache, headache rehabilitation El Paso Texas, multidisciplinary headache care, personal injury headache, nerve block procedure safety, local anesthetic pharmacology, chiropractic manipulation headache, functional medicine El Paso, integrative pain management